



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The Yinota-O-trial: Efficacy of an online yoga-intervention in high-grade glioma patients and their caregivers – patient-reported outcomes and serum stress parameters - a study protocol of a randomized controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-075698
Article Type:	Protocol
Date Submitted by the Author:	16-May-2023
Complete List of Authors:	Rabe, Antonia; University Hospital Würzburg, Psychooncology Keßler, Almuth Friederike; University Hospital Würzburg, Neurosurgical Clinic and Polyclinic, Department of Neurosurgery Hagemann, Carsten; University of Würzburg, Neurosurgical Clinic and Polyclinic, Department of Neurosurgery, Section Experimental Neurosurgery Schubert, Jörg; University Hospital Würzburg, Internal Medicine Center, Central Laboratory Jentschke, Elisabeth ; University Hospital Würzburg, Psychooncology
Keywords:	Quality of Life, Depression & mood disorders < PSYCHIATRY, Anxiety disorders < PSYCHIATRY, Head & neck tumours < ONCOLOGY

SCHOLARONE™
Manuscripts

The Yinota-O-trial: Efficacy of an online yoga-intervention in high-grade glioma patients and their caregivers – patient-reported outcomes and serum stress parameters - a study protocol of a randomized controlled trial

Antonia Rabe¹, Almuth Friederike Keßler², Carsten Hagemann³, Jörg Schubert⁴, Elisabeth Jentschke¹

¹ University Hospital Würzburg, Comprehensive Cancer Center Mainfranken, Department of Psychooncology, Josef-Schneider-Straße 6, 97080 Würzburg, Germany

² University Hospital Würzburg, Neurosurgical Clinic and Polyclinic, Department of Neurosurgery, Josef-Schneider-Straße 11, 97080 Würzburg, Germany

³ University Hospital Würzburg, Neurosurgical Clinic and Polyclinic, Department of Neurosurgery, Section Experimental Neurosurgery, Josef-Schneider-Straße 11, 97080 Würzburg, Germany

⁴ University Hospital Würzburg, Internal Medicine Center, Central Laboratory, Oberdürrbacher Straße 6, 97080 Würzburg, Germany

Correspondence to Dr. phil. Elisabeth Jentschke; jentschke_e@ukw.de

Introduction: High-grade glioma patients and their caregivers often suffer from distress and a lower quality of life. Results from studies with patients with mixed cancer entities suggest that yoga can be an effective support. However, it is unclear whether this also applies to high-grade glioma patients and their caregivers. This study aims to investigate the effects of mindfulness-based online yoga for patients and their caregivers on emotional distress, quality of life and stress-associated physiological parameters compared to a waiting control group (WCG).

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

Methods & analysis: The study is designed as a multicenter randomized controlled trial.

Adult glioma patients (CNS WHO grades 3 & 4) and their caregivers will be recruited.

Experienced yoga instructors deliver the intervention (1 h/week) in a synchronous format over 8 weeks via video conferencing. The WCG will receive standard care during the 8-week waiting period. Data will be collected before and after the end of the intervention and another 3 months later using questionnaires as well as blood serum and hair samples to evaluate biochemical stress parameters. Primary outcome is self-reported generalized anxiety and secondary outcomes are self-reported progression anxiety, depression, quality of life as well as BDNF, DHEA/DHEAS, Ferritin and hair cortisol. We hypothesize better outcomes in the intervention group (IG) compared to the WCG at all measurement points. 70 patients and 70 caregivers will be recruited consecutively. Primary endpoints are significant effect detections in the Generalized Anxiety Disorder Scale-7 of patients and caregivers at the end of the intervention. Analyses of covariance will be performed to analyze treatment effects.

Ethics and dissemination: The Ethics Committee of the University of Würzburg approved the YINOTA-O study on 26.10.2021 (No.185/18-me). Results will be presented at conferences and published in peer-reviewed journals.

Trial registration: German Clinical Trials Register (No. DRKS00029554, 08/2022).

Strengths and limitations of this study

- At the current time, this is the first RCT to analyze the effectiveness of mindfulness-based online yoga for high-grade glioma patients and their caregivers in a synchronous format

- The additional collection of biochemical stress markers could support the validity of self-reports of emotional distress
- The online format provides glioma patients and caregivers of different clinics access to the intervention and could also be beneficial for the target group after covid-19 pandemic
- A limitation is that the inclusion criteria regarding the type of disease (glioma patients CNS WHO grades 3 & 4) and the phase of the disease (diagnosis or recurrence) may induce higher variance of the experienced symptoms among the participants

Introduction

The most recent version of the WHO Classification of Tumors of the Central Nervous System [1] reflects the rapid advances in the understanding of these tumor types [2]. Although a better knowledge of the pathophysiology of these tumors may have a positive impact on the treatment [3], the treatment options for high-grade gliomas remain limited.

Already at the time of diagnosis, glioma patients often report cognitive deficits, seizures, headaches, dizziness, and motor deficits [4]. In addition, during the course of the disease drowsiness, dysphagia, confusion and aphasia are among the most common symptoms [4]. Each of these symptoms might reduce the patients’ autonomy [5]. Therefore, family members frequently provide caregiving, conducting “physically, emotionally, socially and/or financially demanding” tasks [6]. All this suggests an increased burden and a reduced quality of life for patients and caregivers.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

Ståhl and colleagues examined the extent of anxious and depressive symptoms (Hospital Anxiety and Depression Scale) as well as health-related quality of life (SF-36) in both glioblastoma patients and their caregivers before surgery [7]. Caregivers reported significantly inferior health-related quality of life, more anxiety and more depressive symptoms than the patients did. These findings are consistent with those of previous studies [e.g. 8]. They imply that high-grade glioma patients as well as their caregivers should be offered support to deal with disease-related psychological distress.

In recent years, several meta-analyses evaluated the effectiveness of yoga on anxiety and depression in cancer patients [9, 10]. Lin et al. reported a standardized mean difference in favor of yoga of -0.76 (95% CI: -1.34 to -0.19) for anxiety and -0.95 for depression (95% CI: -1.55 to -0.36) [9]. Although, the yoga-styles applied in the analyzed studies varied widely, most yoga-interventions examined in the meta-analyses by Gonzalez et al. were based on Hatha yoga [10]. Yoga interventions had significant effects on depressiveness ($N=1486$, $g=-0.419$, 95% CI=-0.558 to -0.281) and anxiety of cancer patients ($N=977$, $g=-0.347$, 95% CI=-0.473 to -0.221) compared to the control conditions (mainly “no specific therapy”) [10]. Sub-group analyses of different cancer populations were not possible, because the majority of studies was conducted with breast cancer patients. Meanwhile, only one of the included studies examined glioma-patients [11].

Milbury et al. studied the feasibility of a dyadic yoga program for high-grade glioma patients and their caregivers during radiotherapy as well as its effects on cancer-related symptoms [11]. Comparing the intervention group (IG, $n=10$) and the waiting control group (WCG, $n=10$), patients in the IG had significantly lower levels of depressiveness ($d=0.71$) and a significantly higher mental quality of life ($d=0.69$) at post-assessment. Interestingly, in the

caregivers' IG (IG: n=10, WCG n=10) treatment effects were even larger (depressiveness: d=1.12; mental quality of life: d=0.89).

Although these results are promising, seizures can limit the patients' mobility and thereby impede their participation in supportive services on site. Therefore, services, which can be attended from home, might facilitate access to supportive care for the target group.

Nevertheless, only few studies were published examining online yoga interventions [12, 13]. The evaluation of a 12-week asynchronous yoga intervention for myeloproliferative neoplasm patients (n=48) revealed small effects on anxiety and moderate effects on depression at post-assessment [12]. Addington et al. examined a 12-week yoga intervention for breast cancer patients delivered in a synchronic format [13]. Based on qualitative interviews, recommendations for internet-based yoga research were presented.

Beyond subjective indications for the effectiveness of yoga, there is limited evidence in the literature regarding correlation of yoga and stress-associated physiological parameters [12, 14, 15, 16]. However, most of these studies investigated non-cancer patients.

In summary, there is consensus that high-grade glioma patients and their caregivers are highly distressed and that they report reduced quality of life. On-site yoga interventions have positive effects on self-reported emotional well-being of cancer patients. Nevertheless, at this time we are aware of only one American research group investigating the effects of yoga intervention specifically for high-grade glioma patients and their caregivers [11, 17]. Hence, there are still little findings regarding feasibility and efficacy of yoga interventions for high-grade glioma patients and their caregivers, especially if the program is offered online.

To address this research gap, a monocentric on-site pilot study to test feasibility and efficacy of a mindfulness-based yoga intervention for high-grade glioma patients and their caregivers

was started in 2020 and then adapted to an online format due to the COVID-19 pandemic [18]. The initial on-site yoga intervention was already investigated in previous randomized controlled studies in cancer patients with mixed tumor entities and treatment effects on emotional symptoms have been demonstrated [19, 20]. In the pilot study, participants filled questionnaires on disease-related psychological symptoms and quality of life and blood serum and saliva samples were taken. Participants were asked to rate their satisfaction with various course features. When it comes to the online-intervention, known technical problems were reported. However, patients and caregivers' satisfaction with the course was very high. The instructor's guidance was rated most positively. No adverse effects occurred. Overall, the pilot study implies that the online mindfulness-based yoga course is feasible and attractive for the target group, even when offered online and even without previous experience with yoga. The study will continue in a multicenter setting described here to achieve the predefined group size in a timely manner and to reduce the waiting time between recruitment and the start of the intervention. This was difficult to achieve in the monocentric pilot study, because of the rarity of the disease. To measure cortisol, more reliable hair samples will be collected.

Based on the research presented, in this study the following research questions will be examined:

1. Primary research question

- a) Does an 8-week online yoga intervention for high-grade glioma patients and their caregivers reduce self-reported generalized anxiety symptoms directly after the intervention compared to a WCG? *We hypothesize that compared to participants in*

the WCG, participants in the IG report significantly fewer generalized anxiety symptoms after the end of the intervention.

2. Secondary research questions

- a) Does such an intervention reduce self-reported fear of progression directly after the intervention compared to a WCG?
- b) Does such an intervention reduce self-reported depressive symptoms directly after the intervention compared to a WCG?
- c) Does such an intervention improve self-reported quality-of-life directly after the intervention compared to a WCG?
- d) Does such an intervention have a positive effect on stress-associated physiological parameters (BDNF, DHEA/DHEAS, ferritin, hair cortisol) compared to the WCG?
- e) Which changes in self-reported psychological symptoms, quality of life and stress-associated physiological parameters can be observed 3 months after the end of the online yoga intervention?

We hypothesize that the outcomes of participants in the intervention group will be superior to those of participants in the WCG in all aspects (2a-2d) at the end of the intervention.

Methods

Participants

Eligible for the study are adult (≥ 18 years) patients with glioma CNS WHO grades 3 & 4 (initial diagnosis or recurrence) treated in participating hospitals in Germany and their caregivers. Patients are eligible to participate at any time point of treatment, but we recommend joining the yoga program not earlier than six weeks after surgery. Prerequisite for participation is regular access to a mobile device with internet access. Exclusion criteria are insufficient German language skills and serious cognitive, affective, or physical impairments. The study physicians and staff consider exclusion criteria during the recruitment process.

Study centers

Study centers were only eligible to participate in this study if they have the ability to process blood serum samples and store them in a deep-freezer at -80 degrees. In addition, a positive ethics vote by the clinic's own ethics committee was necessary.

Study design and measurement points in time

This is a multicentric randomized controlled trial with an IG and a WCG. First, the IG receives the 8-week online yoga intervention delivered by videoconference (Zoom Video Communications). Subsequently, the WCG receives the same intervention. During the waiting period, the WCG receives the medical standard of care and if necessary additional psychological and supportive care. Measurement points for the IG are: Before randomization (T1), at the end of the intervention (T2) and 3 months after the last scheduled yoga class (T4). Measurement points for the WCG are: Before randomization (T1), at the end of the intervention of the IG/before the start of the intervention of the WCG (T2), at the end of the intervention (T3) and 3 months after the last scheduled yoga class (T5). At each

measurement point in time, questionnaire data as well as a blood serum and hair samples will be collected (Fig. 1)




Figure 1 Study design. IG = Intervention Group, WCG = Waiting Control Group.

Patient and public involvement statement

The study was inspired by the positive experiences of a relative of a brain tumor patient with yoga during the disease and developed in exchange with her. Feedback from participants after the pilot study was considered in the multicenter study.

Yoga-intervention

Participation in the study should be consulted with a physician in advance. Yoga classes are held once a week for 60 minutes. Patients and caregivers will be taught successively in separate groups of 10 participants per group to ensure that caregivers are potentially nearby

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Supérieur (ABES).

in case patients require support. As recommended in the literature [13], the groups will be closed groups. The intervention is based on the mindfulness-based hatha yoga described by Jon Kabatt-Zinn [21]. The intervention is carried out by examined yoga instructors (>200 units). The classes consist of a sequence of breathing exercises (pranayama), physical exercises (asanas) and meditation, which is repeated in each lesson. The exercises were selected in such a way that even patients with advanced disease can perform them with a mindful practice. The intervention is described in detail in Zetzi et al. [20]. For the sake of standardization of the yoga classes, yoga instructors are trained in advance by video-support, demonstrating all the exercises provided. In addition, a booklet is available, describing all exercises and providing important information on possible cancer-specific and cancer non-specific contraindications.

Sample-size calculation

Based on previous research [9], a Standardized Mean Difference (SMD) of 0.76 is expected for generalized anxiety in favor of the IG when comparing the IG to the control group. Consequently, a case number of $n=29$ per group ($\alpha=0.05$ and $\beta=0.20$) will be determined for a two-tailed independent samples t-test. A low proportion of dropouts is expected at the post-intervention time point. Therefore, 70 patients and 70 relatives will be recruited.

Recruitment

Physicians and research staff of participating study centers will identify potential participants utilizing the centers' electronic medical record systems. Suitable persons will be informed about the study either during outpatient consultation in the polyclinics or by phone. If patients and/or their caregivers are interested in study participation, they will receive the

written participation information and the consent form. They approve their participation by signing the latter and sending it by mail to the study coordinator.

Randomization and allocation concealment

Participants will be consecutively enrolled in the study and randomly assigned to the IG or WCG. Utilizing a computer-generated list of random numbers ensures a close balance of the group sizes at any time during the trial by external blocked randomization. The list is generated and managed by an employee who is not involved in the study. If both patients and their caregivers participate in the intervention, they are randomized as a pair. For every block of 20 patients and 20 caregivers, 20 participants (10 patients, 10 caregivers) will be allocated to each arm of the trial.

Data collection, management, and analysis

Data collection

An online questionnaire, blood serum samples and hair samples are used to collect the required data. The online questionnaire is created and administered using the EvaSys evaluation software. Participants can access it via a web-link. On the first page of the online questionnaire, participants are instructed to enter their assignment code, which they received in advance per e-mail.

Primary outcomes

Self-reported generalized anxiety: The German version of the Generalized Anxiety Scale (GAD-7) (22) is used to assess anxious symptoms. Participants are asked to indicate the frequency of perceived impairment by seven symptoms on a 4-point Likert scale (0="not at all" to 4="almost every day") in the last two weeks. The internal consistency is

Cronbachs $\alpha = 0.85$, indicating high reliability [23]. A sum value is calculated from all items (range: 0-21). The higher the value, the greater the severity of the anxiety.

Secondary outcomes

Self-reported fear of progression: The patient questionnaire contains a short form of the Fear of Progression Questionnaire (FoP-Q-SF) with 12 items (PA-F-KF). The answers are given on a five-point Likert scale (1="never"; 5="very often"). Good reliability (Cronbachs $\alpha = 0.87$) and validity were demonstrated in a German sample of breast cancer patients [24]. For analysis, a sum value is calculated from all items (range: 12-60). The higher the value, the greater the severity of the anxiety.

Self-reported depression: The Patient Health Questionnaire-9 (PHQ-9) consists of nine items regarding the impairment due to depressive symptoms in the past two weeks. A 4-point Likert scale is used (0="not at all" to 3="almost every day"). Good reliability (Cronbachs $\alpha = 0.89$) and validity were demonstrated in a sample of patients with different medical conditions [25]. For analysis, a sum score is calculated from all items. The higher the value, the greater the severity of depression (range: 0-27).

Self-reported Quality of Life: The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire C30 (QLQ-C30) plus brain module (BN20) are used to assess quality of life. The EORTC QLQ-C30 consists of 30 questions that can be assigned to ten subscales. Two items assessing overall health and overall quality of life in the last week, both of which were scored from 1="very poor" to 7="excellent". The appropriateness of the other items is assessed on a 4-point Likert scale (1="not all" to 4="very much"). The validity and reliability of the questionnaire could be

demonstrated [26]. Although this is a cancer-specific questionnaire, norm values are also available for a healthy German sample [27].

The brain module is recommended for use in conjunction with the EORTC QLQ-C30 [28]. It consists of additional 20 items that can be assigned to seven single-item scales and four multi-item scales. A standardized point value is calculated by linear transformation. Scores range from 0-100. A higher score for the function scales indicates better functionality, and a higher score for the symptom scales indicates greater symptom burden. Adequate psychometric properties were demonstrated [28].

Stress parameters: To assess stress-associated physiological parameters, the study physicians or the study nurses collect blood serum samples from the participants (20 ml EDTA blood) and pencil-thick strands of hair (2cm, refers to the area of the scalp, length at least 1cm) from the back of the head [29]. The sample procurement points in time for blood serum and hair samples (hair length up to 7 cm) correspond to the time of the questionnaire assessments. For long hair (7 cm or more), one single pencil thick strand of hair will be collected at the last blood serum collection appointment. Hair sampling will not be performed in case of TTFields- or cortisone-treatment.

Sociodemographic and health data: As possible covariates and for sample description, participants will be asked at T1 to provide information regarding marital status, education and occupation, previous experiences with yoga and expectations regarding the classes as well as mental illnesses. In addition, at each measurement point in time, questions are asked about medication, actual treatment and the course of the disease. Patients' routine medical data (type and stage of disease, time of diagnosis, treatment) will be collected from the electronic patient file of the respective clinic by responsible study staff. For the continuous

development of the intervention, participants will be asked about their general and specific satisfaction with individual features of the intervention at the end of the intervention (selected exercises, duration of a single yoga class, and instruction of the exercises, group size, and atmosphere in the class).

Data management

All questionnaire data as well as all blood serum and hair samples are marked with a pseudonym instead of the participant's name and a password-protected digital allocation list is used. The allocation list includes the participant's first and last name, date of birth, the clinic where the participant was recruited, the e-mail address under which the participant would like to be contacted, and whether the participant is a patient or a caregiver. This data is taken from the consent form. The study coordinator, who is responsible for the assignment list, creates a pseudonymization code for each participant according to a predefined procedure. This is required to retrieve the data needed for sample description from the hospital information system as well as to process the blood serum and hair samples. During the period of the assignment, the research data will be considered "personal data" and data protection laws will be complied with.

At the end of data collection, the questionnaire data will be exported from the online platform used for the survey by the study coordinator and saved password-protected on a computer at the University Hospital of Würzburg. After that, the questionnaire data is deleted from the online platform. The site coordinators transmit the selected routine medical data of the participating patients to the study coordinator in accordance with data protection regulations. After data analysis, the assignment lists as well as the consent declarations are deleted. Deletion of the site-specific assignment lists provided will be

confirmed in writing by the site coordinators. The raw data of the study will be destroyed after 10 years in accordance with data protection regulations. To prevent loss of study data, the study coordinator performs a regular backup. Hair samples are enclosed in aluminum foil after collection and the part close to the root is fixed with a paper clip. Samples are stored dry and dark at room temperature in a cardboard box/large envelope. The blood and serum samples, if not completely consumed for molecular stress marker determination, will be stored frozen at -80°C for the duration of the study. After completion of data collection, the samples will be picked up from the participating centers by the medical study management of the University Hospital Würzburg and brought to the laboratory of the Section Experimental Neurosurgery of the Department of Neurosurgery, University Hospital Würzburg. All sample remnants will be destroyed after completion of the study.

Analysis

The data of the patients and the relatives are analyzed separately. To test for group differences (hypotheses 1a – 2d) covariance analyses with adjustment for baseline values of outcome variables will be performed. We use η^2 as the effect size calculated in covariance analyses. $\eta^2=0.0099$ was assessed as a small effect, $\eta^2=0.0588$ as a medium effect, and $\eta^2=0.1379$ as a large effect according to Cohen. To answer hypothesis 2e, a two-tailed t-test is performed. Standardized mean differences are used to calculate the effect size. A p-value of <0.05 is considered significant. Data analysis is performed using International Business Machines Corporation (IBM) Statistical Package for Social Sciences (SPSS) Statistics for Windows version 22. The study results will be published by the participating centers as joint publications in peer-reviewed journals after completion of the data analysis.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

Monitoring

The yoga instructors will document adverse effects, such as injuries, in writing immediately after each class, including necessary adjustments to the exercises.

Ethics and dissemination

The Ethics Committee of the University of Würzburg approved the described study protocol on 26.10.2021 (No.185/18-me). Important changes in the protocol will be passed on to the responsible ethics committee as well as the German Register of Clinical Trials and will be described in study reports. The investigation conforms to the principles outlined in the Declaration of Helsinki. Potential study participants will be informed about all relevant aspects of the study (goals, processes, data protection). This information will be provided verbally and in writing by the research staff. In particular, the voluntary nature of the study participation as well as the possibility of discontinuing the study at any time without giving reasons and without any disadvantages for the treatment are emphasized. In the consent form, interested participants are specifically asked for their consent to provide blood serum and hair samples. They can consent either to provide both samples, to donate blood serum samples or hair samples only, or refuse to give such samples. Even without providing samples, participation in the study is possible. The consent form also asks for an e-mail address for further contact. Participation in the study is only possible with written consent.

Discussion

The disease and its treatment often stress high-grade glioma patients and their caregivers. Depressive and anxious symptoms and reduced quality of life are frequently reported in the literature [7, 8]. Sometimes the emotional health of the caregivers is worse than that of the patients [8]. This multicenter study will offer high-grade glioma patients and their caregivers

a mindfulness-based yoga course by examined yoga instructors, which has already proven helpful in previous studies with patients with mixed cancer entities [19, 20]. However, due to the heterogeneous sample characteristics of these previous studies, it remains unclear whether this yoga intervention is also helpful for improving emotional well-being and quality of life of high-grade glioma patients. In addition, the effectiveness of a mindfulness-based yoga intervention has not yet been studied for caregivers. Generally, yoga studies that exclusively include patients with high-grade glioma and their caregivers are rare [17]. Therefore, in this study the intervention will be provided exclusively for glioma patients CNS WHO grades 3 and 4 and their caregivers.

The aim of this randomized controlled study is to investigate whether significant changes of self-reported anxious and depressive symptoms and in quality of life are detectable after the intervention in the IG compared to the WCG. As in previous yoga studies [e.g. 10], self-report questionnaires will be used for this purpose. Furthermore, stress-associated physiological parameters extracted from blood and hair samples are also evaluated in this study. A possible demonstration of the effects of mindfulness-based online yoga therapy on a biochemical level could highlight the value of yoga in the supportive therapy of cancer patients and should be further investigated in future studies. Although the inclusion criteria regarding the type of disease (glioma patients CNS WHO grades 3 & 4) and the phase of the disease (diagnosis or recurrence) facilitate timely recruitment of the participants, they may also induce higher variance of the experienced limitations among the participants. In favor of greater homogeneity, specification of inclusion criteria regarding characteristics of the tumors based on the updated WHO Classification [1] is considered for this and recommended for future studies.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

Due to the Covid-19 pandemic the yoga intervention, which we planned originally as an in-person course was adapted to an online format. Today, we expect this to actually bring other advantages for the vulnerable target group in comparison to on-site yoga. The participation in the online course may increase the sense of autonomy of patients with reduced mobility, as they do not need to be driven to class by family members. It also conserves caregivers' limited time resources due to caregiving and may reduce stress from travel. For this reason, the online yoga therapy if proven effective could be an attractive treatment approach for high-grade glioma patients and their caregivers even beyond the Covid-19 pandemic.

References

1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. *Neuro-oncology* 2021;23(8):1231-51.
2. Horbinski C, Berger T, Packer RJ, et al. Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours. *Nature Reviews Neurology* 2022;18(9):515-29.
3. Wen PY, Packer RJ. The 2021 WHO classification of tumors of the central nervous system: clinical implications. *Neuro-oncology* 2021;23(8):1215-7.
4. IJzerman-Korevaar M, Snijders TJ, de Graeff A, et al. Prevalence of symptoms in glioma patients throughout the disease trajectory: a systematic review. *Journal of neuro-oncology* 2018;140:485-96.
5. Sterckx W, Coolbrandt A, de Casterlé BD, et al. The impact of a high-grade glioma on everyday life: a systematic review from the patient's and caregiver's perspective. *European Journal of Oncology Nursing* 2013;17(1):107-17.

6. Schubart JR, Kinzie MB, Farace E. Caring for the brain tumor patient: family caregiver burden and unmet needs. *Neuro-oncology* 2008;10(1):61-72.
7. Ståhl P, Fekete B, Henoch I, et al. Health-related quality of life and emotional well-being in patients with glioblastoma and their relatives. *Journal of Neuro-oncology* 2020;149:347-56.
8. Renovanz M, Maurer D, Lahr H, et al. Supportive care needs in glioma patients and their caregivers in clinical practice: results of a multicenter cross-sectional study. *Frontiers in neurology* 2018;9:763.
9. Lin K-Y, Hu Y-T, Chang K-J, et al. Effects of yoga on psychological health, quality of life, and physical health of patients with cancer: a meta-analysis. *Evidence-Based Complementary and Alternative Medicine* 2011:1-12.
10. Gonzalez M, Pascoe MC, Yang G, et al. Yoga for depression and anxiety symptoms in people with cancer: a systematic review and meta-analysis. *Psycho-Oncology* 2021;30(8):1196-208.
11. Milbury K, Li J, Weathers S-P, et al. Pilot randomized, controlled trial of a dyadic yoga program for glioma patients undergoing radiotherapy and their family caregivers. *Neuro-Oncology Practice* 2019;6(4):311-20.
12. Huberty J, Eckert R, Dueck A, et al. Online yoga in myeloproliferative neoplasm patients: results of a randomized pilot trial to inform future research. *BMC complementary and alternative medicine* 2019;19(1):1-12.
13. Addington EL, Sohl SJ, Tooze JA, et al. Convenient and Live Movement (CALM) for women undergoing breast cancer treatment: Challenges and recommendations for internet-based yoga research. *Complementary therapies in medicine* 2018;37:77-9.

14. Cahn BR, Goodman MS, Peterson CT, et al. Yoga, meditation and mind-body health: increased BDNF, cortisol awakening response, and altered inflammatory marker expression after a 3-month yoga and meditation retreat. *Frontiers in human neuroscience* 2017;11:1-13.
15. Kumar D. Role of yoga and meditation on serum DHEAS level in first year medical students. *International Journal of Research in Medical Sciences* 2018;6(6):2018-22.
16. Thirthalli J, Naveen G, Rao M, et al. Cortisol and antidepressant effects of yoga. *Indian journal of psychiatry* 2013;55(3):405-8.
17. Milbury K, Mallaiah S, Mahajan A, et al. Yoga program for high-grade glioma patients undergoing radiotherapy and their family caregivers. *Integrative cancer therapies* 2018;17(2):332-6.
18. Jentschke E, Rabe A, Hagemann C, et al. The YINOTA-trial: Efficacy of Yoga-intervention in high grade glioma patients and their caregivers - patient-reported outcomes and serum stress parameters In: Karger, editor. 35. Deutscher Krebsskongress, Krebsmedizin: Schnittstellen zwischen Innovation und Versorgung 13.-16.11.2022 Berlin Oncology Research and Treatment 2022: 485
19. Hardoerfer K, Jentschke E. Effect of Yoga Therapy on Symptoms of Anxiety in Cancer Patients. *Oncol Res Treat* 2018;41(9):526-32.
20. Zetzel T, Renner A, Pittig A, et al. Yoga effectively reduces fatigue and symptoms of depression in patients with different types of cancer. *Supportive Care in Cancer* 2021;29:2973-82.
21. Kabat-Zinn J. *Gesund durch Meditation. Das große Buch der Selbstheilung mit MBSR* Knaur Menssana 2013.

22. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of internal medicine 2006;166(10):1092-7.

23. Hinz A, Klein AM, Brähler E, et al. Psychometric evaluation of the Generalized Anxiety Disorder Screener GAD-7, based on a large German general population sample. Journal of affective disorders 2017;210:338-44.

24. Mehnert A, Herschbach P, Berg P, et al. Progredienzangst bei Brustkrebspatientinnen-Validierung der Kurzform des Progredienzangstfragebogens PA-F-KF. Zeitschrift für Psychosomatische Medizin und Psychotherapie 2006;52(3):274-88.

25. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. Journal of general internal medicine 2001;16(9):606-13.

26. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. JNCI: Journal of the National Cancer Institute 1993;85(5):365-76.

27. Nolte S, Waldmann A, Liegl G, et al. Updated EORTC QLQ-C30 general population norm data for Germany. European Journal of Cancer 2020;137:161-70.

28. Taphoorn MJ, Claassens L, Aaronson NK, et al. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. European Journal of Cancer 2010;46(6):1033-40.

29. Preanalytics and shipping of hair samples for steroid analysis [online]. <https://tu-dresden.de/mn/psychologie/ifap/biopsychologie/ressourcen/dateien/labor/instructions-on-labelling-and-shipping-hair-samples?lang=de> (accessed: 27.02.2023).

Footnotes

Ethics approval and consent to participate

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

The study conforms to the principles outlined in the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of the University Würzburg on 26.10.2021 (No.185/18-me). In addition, the study is registered in the German Register of Clinical Trials (No. DRKS00029554, 08/2022). Any changes to the study protocol must be approved by the responsible ethics committee and reported to the German Clinical Trials Registry. Potential participants will be informed about the study verbally and in writing. Written informed consent must be given for study participation.

Consent for publication

Not applicable.

Availability of data and materials

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Funding

Not applicable.

Authors' contributions

EJ is the psychological study director and AK is the medical study director. CH and JS will supervise the collection of the biomarkers and analyze them. AR is responsible for the implementation and the coordination of the study. All authors read and approved the final manuscript.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

The authors would like to thank Dr. med. Miriam Ratliff, Neurooncology Center Mannheim, Neurosurgical Clinic, University Hospital Mannheim;


Prof. Dr. med. Giles Hamilton Vince, Neurosurgical Clinic, Aschaffenburg-Alzenau Hospital, Dr. med. Donato Daniel Martellotta, Neurosurgical Clinic, Aschaffenburg-Alzenau Hospital;

Prof. Dr. med. Martin Glas, Department of Clinical Neurooncology, Department of Neurology, Essen University Hospital, PD Dr. med. Sied Kebir, Department of Clinical Neurooncology, Department of Neurology, Essen University Hospital, Dr. Sarina Agkatsev, DPhil, Department of Clinical Neurooncology, Department of Neurology, Essen University Hospital;

Prof. Dr. med. Ehab Shiban, Department of Neurosurgery, Augsburg University Hospital, PD Dr. med. habil. Björn Sommer, Department of Neurooncology, Clinic for Neurosurgery, Augsburg University Hospital, Dr. med. Ina Konietzko, Clinic for Neurosurgery, Augsburg University Hospital;

Prof. Dr. med. Georg Karpel-Massler, Clinic for Neurosurgery, University Hospital Ulm and Dr. Stephanie Otto, Comprehensive Cancer Center Ulm, University Hospital Ulm for their letter of intent to participate in the multicenter study.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).



BMJ Open

Study protocol for a multicenter randomized controlled trial evaluating the efficacy of an online yoga-intervention in high-grade glioma patients and their caregivers: The YINOTA-O-trial

Journal:	BMJ Open
Manuscript ID	bmjopen-2023-075698.R1
Article Type:	Protocol
Date Submitted by the Author:	22-Jan-2024
Complete List of Authors:	Rabe, Antonia; University Hospital Wurzburg, Psychooncology Keßler, Almuth Friederike; University Hospital Wurzburg, Neurosurgical Clinic and Polyclinic, Department of Neurosurgery Hagemann, Carsten; University Hospital Wurzburg, Neurosurgical Clinic and Polyclinic, Department of Neurosurgery, Section Experimental Neurosurgery Schubert, Jörg; University Hospital Wurzburg, Internal Medicine Center, Central Laboratory Jentschke, Elisabeth ; University Hospital Wurzburg, Psychooncology
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Mental health
Keywords:	Quality of Life, Depression & mood disorders < PSYCHIATRY, Anxiety disorders < PSYCHIATRY, Head & neck tumours < ONCOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Study protocol for a multicenter randomized controlled trial evaluating the efficacy of an online yoga-intervention in high-grade glioma patients and their caregivers: The YINOTA-O-trial

Antonia Rabe¹, Almuth Friederike Keßler², Carsten Hagemann³, Jörg Schubert⁴, Elisabeth Jentschke¹

¹ University Hospital Würzburg, Comprehensive Cancer Center Mainfranken, Department of Psychooncology, Josef-Schneider-Straße 6, 97080 Würzburg, Germany

²University Hospital Würzburg, Neurosurgical Clinic and Polyclinic, Department of Neurosurgery, Josef-Schneider-Straße 11, 97080 Würzburg, Germany

³University Hospital Würzburg, Neurosurgical Clinic and Polyclinic, Department of Neurosurgery, Section Experimental Neurosurgery, Josef-Schneider-Straße 11, 97080 Würzburg, Germany

⁴University Hospital Würzburg, Internal Medicine Center, Central Laboratory, Oberdürrbacher Straße 6, 97080 Würzburg, Germany

Correspondence to Dr. phil. Elisabeth Jentschke: jentschke_e@ukw.de

Introduction: High-grade glioma patients and their caregivers often suffer from distress and a lower quality of life. Results from studies with patients with mixed cancer entities suggest that yoga can be an effective support. However, it is unclear whether this also applies to high-grade glioma patients and their caregivers. This study aims to investigate the effects of mindfulness-based online yoga for patients and their caregivers on emotional distress, quality of life and stress-associated physiological parameters compared to a waiting control group (WCG).

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

Methods & analysis: The study is designed as a multicenter randomized controlled trial. Adult glioma patients (CNS WHO grades 3 & 4) and their caregivers will be recruited. Examined yoga instructors deliver the intervention (1 h/week) in a synchronous format over 8 weeks via video conferencing. The WCG will receive standard care during the 8-week waiting period. Data will be collected before and after the end of the intervention and another 3 months later using questionnaires as well as blood serum and hair samples to evaluate biochemical stress parameters. Primary outcome is self-reported generalized anxiety and secondary outcomes are self-reported progression anxiety, depression, quality of life as well as BDNF, DHEA/DHEAS, Ferritin and hair cortisol. We hypothesize better outcomes in the intervention group (IG) compared to the WCG at all measurement points. 70 patients and 70 caregivers will be recruited consecutively. Primary endpoints are significant effect detections in the Generalized Anxiety Disorder Scale-7 of patients and caregivers at the end of the intervention. Analyses of covariance will be performed to analyze treatment effects.

Ethics and dissemination: The Ethics Committee of the University of Würzburg approved the YINOTA-O study on 26.10.2021 (No.185/18-me). Results will be presented at conferences and published in peer-reviewed journals.

Trial registration: German Clinical Trials Register (No. DRKS00029554, 08/2022).

Strengths and limitations of this study

- Simultaneous collection of subjective questionnaire data and objective physiological parameters
- Implementation of a tailored yoga intervention designed specifically to meet the unique needs of cancer patients

- The inclusion in the study without pre-screening for the identification of distressed patients and caregivers may influence the detection of treatment effects
- The inclusion criteria regarding the type of disease (glioma patients CNS WHO grades 3 & 4) and the phase of the disease (diagnosis or recurrence) may induce higher variance of the experienced symptoms among the participants

Introduction

The most recent version of the WHO Classification of Tumors of the Central Nervous System [1] reflects the rapid advances in the understanding of brain tumors [2]. While a better understanding of the pathophysiology of these tumors may have a positive impact on the treatment [3], the treatment options for high-grade gliomas remain limited.

At the time of diagnosis, glioma patients often report cognitive deficits, seizures, headaches, dizziness, and motor deficits [4]. As the disease progresses, drowsiness, dysphagia, confusion, and aphasia expand the list of symptoms [4] and can reduce the patients’ autonomy [5]. Family members frequently take on the role of caregivers, conducting “physically, emotionally, socially and/or financially demanding” tasks [6]. Thus the diagnosis of a high grade glioma imposes a burden and significant reduction in quality of life for both the patients and their caregivers. Ståhl and colleagues examined the extent of anxious and depressive symptoms as well as health-related quality of life in both glioblastoma patients and their caregivers before surgery [7]. Caregivers reported significantly inferior health-related quality of life, more anxiety, and more depressive symptoms than the patients did. These findings are consistent with those of previous studies [e.g. 8]. They imply that high-grade glioma patients as well as their caregivers should be offered support to deal with disease-related psychological distress.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

Yoga is increasingly recognized as a complementary therapy for improving quality of life and cancer-related symptoms [9]. In recent years, several meta-analyses evaluated the effectiveness of yoga on anxiety and depression in cancer patients [10, 11]. Lin et al. as well as Gonzalez et al. reported significant medium effects of yoga on anxiety and significant medium to large effects on depression compared to the control conditions [10,11]. Most studies were conducted with breast cancer patients which is why no meta insights can be derived for the glioma patient population.

One referenced study examined a yoga intervention for glioma patients in an on-site setting [12]. Milbury et al. studied the feasibility of a dyadic yoga program for high-grade glioma patients and their caregivers during radiotherapy as well as its effects on cancer-related symptoms [12]. Comparing the intervention group and the waiting control group, patients in the intervention group showed significantly lower levels of depression and a significantly higher mental quality of life at post-assessment. In the caregivers' intervention group treatment effects were even more pronounced with a large effect size for improvement in depression. These results are encouraging but due to the on-site course format, require the physical presence of participants at the course location. Seizures can limit the patients' mobility and thereby impede their participation in supportive services on site. Alternatively, services, which can be attended from home, e.g. in an online format, could facilitate access supportive care for the target group. To date, only few studies were published examining online yoga interventions [13, 14]. None of them concern the group of glioma patients. The initial indications of feasibility cannot be generalized to brain tumor patients as they have brain tumor-specific symptoms like motor deficits [4] that need to be dealt with. In order to provide individual support from the yoga teachers, a synchronous online format seems appropriate for the target group but has not yet been investigated. It allows interaction with

the instructor as well as simultaneous supervision. To evaluate the feasibility of such an intervention for both patients and their caregivers, a monocentric pilot study was conducted in 2020, demonstrating its practicality and participant satisfaction [15].

The use of subjective measurement tools for assessing potential effects of yoga interventions on anxiety and depression seems appropriate, given the subjective nature of these criteria. Nonetheless, it remains unclear whether intervention effects are also detectable at the biological level. Initial indications of the effects of yoga interventions on biological parameters are derived from studies involving non-clinical populations [16, 17, 18] as well as patients with myeloproliferative neoplasms [13]; evidence for glioma patients and their caregivers is missing.

Based on the research presented, in this study the following research questions will be examined:

1. Primary research question

Does an eight-week online yoga intervention for high-grade glioma patients and their caregivers reduce self-reported generalized anxiety symptoms directly after the intervention compared to a WCG? *We hypothesize that compared to participants in the WCG, participants in the IG will report significantly fewer generalized anxiety symptoms after the end of the intervention.*

2. Secondary research question

Does such an intervention reduce self-reported fear of progression, depressive symptoms, quality of life and stress-associated physiological parameters (BDNF, DHEA/DHEAS, ferritin, hair cortisol) directly after the intervention compared to a

WCG? We hypothesize that the outcomes of participants in the intervention group will be superior to those of participants in the WCG in all aspects at the end of the intervention.

Moreover, employing an explorative approach, the changes in self-reported psychological symptoms, quality of life and stress-associated physiological parameters 3 months after the end of the online yoga intervention should be investigated.

Methods

Participants

Eligible for the study are adult (≥ 18 years) patients with glioma CNS WHO grades 3 & 4 (initial diagnosis or recurrence) treated in participating hospitals in Germany (University Hospital Würzburg, University Hospital Mannheim, Aschaffenburg-Alzenau Hospital, University Hospital Augsburg) and their caregivers. Patients are eligible to participate at any time point of treatment, but we recommend joining the yoga program not earlier than six weeks after surgery. Prerequisite for participation is regular access to a mobile device with internet access. Exclusion criteria are insufficient German language skills and serious cognitive, affective, or physical impairments. The study physicians and staff consider exclusion criteria during the recruitment process. Participants are advised not to concurrently engage in other supportive interventions for psychological distress throughout the duration of the study.

Study centers

Study centers were only eligible to participate in this study if they have the ability to process blood serum samples and store them in a deep-freezer at -80 degrees. Moreover, a positive ethics approval from the hospital's internal ethics committee and the execution of a

1
2
3 135 cooperation agreement were mandatory. Other clinics in Germany, excluding those
4
5
6 136 mentioned, are still in the process of fulfilling these requirements.
7
8

9 137 Study design and measurement points in time

10
11
12 138 This is a multicentric randomized controlled trial with an IG and a WCG. First, the IG receives
13
14 139 the 8-week online yoga intervention delivered by videoconference (Zoom Video
15
16
17 140 Communications). Subsequently, the WCG receives the same intervention. During the waiting
18
19 141 period, the WCG receives the medical standard of care and if necessary additional
20
21 142 psychological and supportive care. The latter was determined for ethical reasons.
22
23
24 143 Measurement points for the IG are: Before randomization (T1), at the end of the intervention
25
26 144 (T2) and 3 months after the last scheduled yoga class (T4). Measurement points for the WCG
27
28 145 are: Before randomization (T1), at the end of the intervention of the IG/before the start of the
29
30 146 intervention of the WCG (T2), at the end of the intervention (T3) and 3 months after the last
31
32 147 scheduled yoga class (T5). At each measurement point in time, questionnaire data as well as
33
34 148 a blood serum and hair samples will be collected (Fig. 1). Study staff will supervise the status
35
36 149 of data collection and, if necessary, contact participants by telephone if assessments are
37
38
39 150 missing. The planned start of the study is January 2024 and the expected end of the study is
40
41
42
43 151 January 2026. Table 1 shows the study workflow.
44
45
46

47 **Table 1.** Schedule of enrolment, interventions, and assessments, according to Spirit 2013
48 guidelines
49

50 152

51
52
53
54
55
56
57
58
59
60

	Enrolment	Before allocation	After T1	Post-allocation			
TIMEPOINT	-T ₁	T1		T2	T3	T4	T5

					(only WCG)	(only IG)	(only WCG)
ENROLMENT:							
Eligibility screen	x						
Informed consent	x						
Allocation			x				
INTERVENTIONS:							
Online Yoga (IG)				↔			
Online Yoga (WCG)					↔		
ASSESSMENTS:							
socio-demographic data		x					
Medical data		x		x	x	x	x
Generalized anxiety		x		x	x	x	x
Fear of progression (only patients)		x		x	x	x	x
Depression		x		x	x	x	x
Quality of Life Questionnaire + Brain Module (only patients)		x		x	x	x	x
BDNF, DHEA/DHEAS, ferritin, hair cortisol		x		x	x	x	x
Evaluation						x	x

Patient and public involvement statement

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The study was inspired by the positive experiences of a relative of a brain tumor patient with yoga during the disease and developed in exchange with her. Feedback from participants after the pilot study [15] was considered in the multicenter study.

Yoga intervention

Participation in the study should be consulted with a physician in advance. Yoga classes are held once a week for 60 minutes. Patients and caregivers will be taught successively in separate groups of 10 participants per group to ensure that caregivers are potentially nearby in case patients require support. As recommended in the literature [14], the groups will be closed groups. The intervention is based on the mindfulness-based hatha yoga described by Jon Kabatt-Zinn [19]. The intervention is carried out by examined yoga instructors (>200 units). The classes consist of a sequence of breathing exercises (pranayama), physical exercises (asanas) and meditation, which is repeated in each lesson. The exercises were selected in such a way that even patients with advanced disease can perform them with a mindful practice. The intervention is described in detail in Zetzi et al. [20]. For the sake of standardization of the yoga classes, yoga instructors are trained in advance by video-support, demonstrating all the exercises provided. Alternative variations of the exercises will be discussed during the training session for participants who may face challenges in performing certain exercises due to impairments. In addition, a booklet is available, describing all exercises and providing important information on possible cancer-specific and cancer non-specific contraindications. To minimize technical difficulties, participants will be offered a technical rehearsal, and they will receive instructions on using the video platform.

Sample-size calculation

Based on previous research [10], a Standardized Mean Difference (SMD) of 0.76 is expected

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

178 for generalized anxiety in favor of the IG when comparing the IG to the control group.

179 Consequently, a case number of $n=29$ per group ($\alpha=0.05$ and $\beta=0.20$) will be determined
180 for a two-tailed independent samples t-test. A low proportion of dropouts is expected at the
181 post-intervention time point. Therefore, 70 patients and 70 relatives will be recruited.

182 Recruitment

183 Physicians and research staff of participating study centers will identify potential participants
184 utilizing the centers' electronic medical record systems. Suitable persons will be informed
185 about the study either during outpatient consultation in the polyclinics or by phone. If patients
186 and/or their caregivers are interested in study participation, they will receive the written
187 participation information and the consent form. They approve their participation by signing
188 the latter and sending it by mail to the study coordinator. Recruitment will be concluded once
189 the required sample size is reached.

190 Randomization and allocation concealment

191 Participants will be consecutively enrolled in the study and randomly assigned to the IG or
192 WCG. Utilizing a computer-generated list of random numbers ensures a close balance of the
193 group sizes at any time during the trial by external blocked randomization (allocation rate 1:1).
194 The list is generated and managed by an employee of the University Hospital Würzburg who
195 is not involved in the study. If both patients and their caregivers participate in the intervention,
196 they are randomized as a pair. For every block of 20 patients and 20 caregivers, 20 participants
197 (10 patients, 10 caregivers) will be allocated to each arm of the trial. The study coordinator
198 will request the results of the randomization after the initial survey is completed and convey
199 it to the participants. Participants are then no longer blinded. If there is a likelihood of missing
200 two sessions, randomization will be delayed.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

201 **Data collection, management, and analysis**

202 Data collection

203 An online questionnaire, blood serum samples and hair samples are used to collect the
204 required data. The online questionnaire is created and administered using the EvaSys
205 evaluation software. Participants can access it via a web-link. On the first page of the online
206 questionnaire, participants are instructed to enter their assignment code, which they received
207 in advance per e-mail.

208 Primary outcomes

209 *Self-reported generalized anxiety:* The German version of the Generalized Anxiety Scale (GAD-
210 7) [21] is used to assess anxious symptoms. Participants are asked to indicate the frequency
211 of perceived impairment by seven symptoms on a 4-point Likert scale
212 (0="not at all" to 4="almost every day") in the last two weeks. The internal consistency is
213 Cronbachs $\alpha = 0.85$, indicating high reliability [22]. A sum value is calculated from all items
214 (range: 0-21). The higher the value, the greater the severity of the anxiety.

215 Secondary outcomes

216 *Self-reported fear of progression:* The patient questionnaire contains a short form of the Fear
217 of Progression Questionnaire (FoP-Q-SF) with 12 items (PA-F-KF). The answers are given on a
218 five-point Likert scale (1="never"; 5="very often"). Good reliability (Cronbachs $\alpha = 0.87$) and
219 validity were demonstrated in a German sample of breast cancer patients [23]. For analysis, a
220 sum value is calculated from all items (range: 12-60). The higher the value, the greater the
221 severity of the anxiety.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

222 *Self-reported depression:* The Patient Health Questionnaire-9 (PHQ-9) consists of nine items
223 regarding the impairment due to depressive symptoms in the past two weeks. A 4-point Likert
224 scale is used (0="not at all" to 3="almost every day"). Good reliability (Cronbachs $\alpha = 0.89$)
225 and validity were demonstrated in a sample of patients with different medical conditions [24].
226 For analysis, a sum score is calculated from all items. The higher the value, the greater the
227 severity of depression (range: 0-27).

228 *Self-reported Quality of Life:* The European Organization for Research and Treatment of Cancer
229 (EORTC) Quality of Life questionnaire C30 (QLQ-C30) plus brain module (BN20) are used to
230 assess quality of life. The EORTC QLQ-C30 consists of 30 questions that can be assigned to ten
231 subscales. Two items assessing overall health and overall quality of life in the last week, both
232 of which were scored from 1="very poor" to 7="excellent". The appropriateness of the other
233 items is assessed on a 4-point Likert scale (1="not all" to 4="very much"). The validity and
234 reliability of the questionnaire could be demonstrated [25]. Although this is a cancer-specific
235 questionnaire, norm values are also available for a healthy German sample [26].

236 The brain module is recommended for use in conjunction with the EORTC QLQ-C30 [27]. It
237 consists of additional 20 items that can be assigned to seven single-item scales and four multi-
238 item scales. A standardized point value is calculated by linear transformation. Scores range
239 from 0-100. A higher score for the function scales indicates better functionality, and a higher
240 score for the symptom scales indicates greater symptom burden. Adequate psychometric
241 properties were demonstrated [27].

242 *Stress parameters:* To assess stress-associated physiological parameters, the study physicians
243 or the study nurses collect blood serum samples from the participants (20 ml EDTA blood) and
244 pencil-thick strands of hair (2cm, refers to the area of the scalp, length at least 1cm) from the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

back of the head [28]. The sample procurement points in time for blood serum and hair samples (hair length up to 7 cm) correspond to the time of the questionnaire assessments. For long hair (7 cm or more), one single pencil thick strand of hair will be collected at the last blood serum collection appointment. Hair sampling will not be performed in case of TTFields- or cortisone-treatment.

Sociodemographic and health data: As possible covariates and for sample description, participants will be asked at T1 to provide information regarding marital status, education and occupation, previous experiences with yoga and expectations regarding the classes as well as mental illnesses. In addition, at each measurement point in time, questions are asked about medication, actual treatment and the course of the disease. Patients' routine medical data (type and stage of disease, time of diagnosis, treatment) will be collected from the electronic patient file of the respective clinic by responsible study staff. For the continuous development of the intervention, participants will be asked about their general and specific satisfaction with individual features of the intervention at the end of the intervention (selected exercises, duration of a single yoga class, and instruction of the exercises, group size, and atmosphere in the class).

Data management

All questionnaire data as well as all blood serum and hair samples are marked with a pseudonym instead of the participant's name and a password-protected digital allocation list is used. The allocation list includes the participant's first and last name, date of birth, the clinic where the participant was recruited, the e-mail address under which the participant would like to be contacted, and whether the participant is a patient or a caregiver. This data is taken from the consent form. The study coordinator, who is responsible for the assignment list,

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

creates a pseudonymization code for each participant according to a predefined procedure. This is required to retrieve the data needed for sample description from the hospital information system as well as to process the blood serum and hair samples. During the period of the assignment, the research data will be considered “personal data” and data protection laws will be complied with.

At the end of data collection, the questionnaire data will be exported from the online platform used for the survey by the study coordinator and saved password-protected on a computer at the University Hospital of Würzburg. After that, the questionnaire data is deleted from the online platform. The site coordinators transmit the selected routine medical data of the participating patients to the study coordinator in accordance with data protection regulations. After data analysis, the assignment lists as well as the consent declarations are deleted. Deletion of the site-specific assignment lists provided will be confirmed in writing by the site coordinators. The raw data of the study will be destroyed after 10 years in accordance with data protection regulations. To prevent loss of study data, the study coordinator performs a regular backup. Hair samples are enclosed in aluminum foil after collection and the part close to the root is fixed with a paper clip. Samples are stored dry and dark at room temperature in a cardboard box/large envelope. The blood and serum samples, if not completely consumed for molecular stress marker determination, will be stored frozen at -80°C for the duration of the study. After completion of data collection, the samples will be picked up from the participating centers by the medical study management of the University Hospital Würzburg and brought to the laboratory of the Section Experimental Neurosurgery of the Department of Neurosurgery, University Hospital Würzburg. The analysis of the biological data is blinded. All sample remnants will be destroyed after completion of the study.

Analysis

1
2
3 292 Intent-to-treat as well as per protocol analyses should be performed. Participants who
4
5 293 attended at least six out of the eight sessions are considered completers. The data of the
6
7
8 294 patients and the relatives are analyzed separately. To test for group differences covariance
9
10 295 analyses with adjustment for baseline values of outcome variables will be performed. We use
11
12
13 296 η^2 as the effect size calculated in covariance analyses. $\eta^2=0.0099$ was assessed as a small
14
15 297 effect, $\eta^2=0.0588$ as a medium effect, and $\eta^2=0.1379$ as a large effect according to Cohen.
16
17
18 298 To analyze changes between post-intervention and follow-up two-tailed t-tests are
19
20 299 performed. Standardized mean differences are used to calculate the effect size. A p-value of
21
22
23 300 <0.05 is considered significant. Missing values due to drop-out will be analyzed by pair-wise
24
25 301 deletion.

26
27
28 302 Data analysis is performed using International Business Machines Corporation (IBM) Statistical
29
30 303 Package for Social Sciences (SPSS) Statistics for Windows version 22.

31
32
33
34 304 **Monitoring**

35
36
37 305 The yoga instructors will document adverse effects, such as injuries, in writing immediately
38
39 306 after each class, including necessary adjustments to the exercises. The documentation of
40
41
42 307 presence is used to calculate the adherence rate.

43
44
45 308 **Ethics and dissemination**

46
47
48 309 The Ethics Committee of the University of Würzburg approved the described study protocol
49
50 310 on 26.10.2021 (No.185/18-me). Important changes in the protocol will be passed on to the
51
52
53 311 responsible ethics committee as well as the German Register of Clinical Trials and will be
54
55
56 312 described in study reports. The investigation conforms to the principles outlined in the
57
58 313 Declaration of Helsinki. Potential study participants will be informed about all relevant aspects
59
60 314 of the study (goals, processes, data protection). This information will be provided verbally and

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

in writing by the research staff. In particular, the voluntary nature of the study participation as well as the possibility of discontinuing the study at any time without giving reasons and without any disadvantages for the treatment are emphasized. In the consent form, interested participants are specifically asked for their consent to provide blood serum and hair samples. They can consent either to provide both samples, to donate blood serum samples or hair samples only, or refuse to give such samples. Even without providing samples, participation in the study is possible. The consent form also asks for an e-mail address for further contact. Participation in the study is only possible with written consent. After completion of the study, a joint publication of the study results has been contractually agreed between the participating clinics. There are no publication restrictions. No professional writers are planned.

Discussion

The disease and its treatment often stress high-grade glioma patients and their caregivers. Depressive and anxious symptoms and reduced quality of life are frequently reported in the literature [7, 8]. Sometimes the emotional health of the caregivers is worse than that of the patients [8]. This multicenter study will offer high-grade glioma patients and their caregivers a mindfulness-based yoga course by examined yoga instructors, which has already proven helpful in previous studies with patients with mixed cancer entities [20, 29]. However, due to the heterogeneous sample characteristics of these previous studies, it remains unclear whether this yoga intervention is also helpful for improving emotional well-being and quality of life of high-grade glioma patients. In addition, the effectiveness of a mindfulness-based yoga intervention has not yet been studied for caregivers. Generally, yoga studies that exclusively include patients with high-grade glioma and their caregivers are rare [12]. Therefore, in this study the intervention will be provided exclusively for glioma patients CNS WHO grades 3 and 4 and their caregivers.

The aim of this randomized controlled study is to investigate whether significant changes of self-reported anxious and depressive symptoms and in quality of life are detectable after the intervention in the IG compared to the WCG. As in previous yoga studies [e.g. 11], self-report questionnaires will be used for this purpose. Furthermore, stress-associated physiological parameters extracted from blood and hair samples are also evaluated in this study. A possible demonstration of the effects of mindfulness-based online yoga therapy on a biochemical level could highlight the value of yoga in the supportive therapy of cancer patients and should be further investigated in future studies. Although the inclusion criteria regarding the type of disease (glioma patients CNS WHO grades 3 & 4) and the phase of the disease (diagnosis or recurrence) facilitate timely recruitment of the participants, they may also induce higher variance of the experienced limitations among the participants. In favor of greater homogeneity, specification of inclusion criteria regarding characteristics of the tumors based on the updated WHO Classification [1] is considered for this and recommended for future studies.

Due to the Covid-19 pandemic the yoga intervention, which we planned originally as an in-person course was adapted to an online format. Today, we expect this to actually bring other advantages for the vulnerable target group in comparison to on-site yoga. The participation in the online course may increase the sense of autonomy of patients with reduced mobility, as they do not need to be driven to class by family members. It also conserves caregivers' limited time resources due to caregiving and may reduce stress from travel. For this reason, the online yoga therapy if proven effective could be an attractive treatment approach for high-grade glioma patients and their caregivers even beyond the Covid-19 pandemic.

References

- 1
2
3 362 1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the
4
5
6 363 central nervous system: a summary. *Neuro-oncology* 2021;23(8):1231-51.
7
- 8 364 2. Horbinski C, Berger T, Packer RJ, et al. Clinical implications of the 2021 edition of the
9
10 365 WHO classification of central nervous system tumours. *Nature Reviews Neurology*
11
12 366 2022;18(9):515-29.
13
- 14
15 367 3. Wen PY, Packer RJ. The 2021 WHO classification of tumors of the central nervous
16
17 368 system: clinical implications. *Neuro-oncology* 2021;23(8):1215-7.
18
- 19
20 369 4. IJzerman-Korevaar M, Snijders TJ, de Graeff A, et al. Prevalence of symptoms in glioma
21
22 370 patients throughout the disease trajectory: a systematic review. *Journal of neuro-oncology*
23
24 371 2018;140:485-96.
25
- 26
27 372 5. Sterckx W, Coolbrandt A, de Casterlé BD, et al. The impact of a high-grade glioma on
28
29 373 everyday life: a systematic review from the patient's and caregiver's perspective. *European*
30
31 374 *Journal of Oncology Nursing* 2013;17(1):107-17.
32
- 33
34 375 6. Schubart JR, Kinzie MB, Farace E. Caring for the brain tumor patient: family caregiver
35
36 376 burden and unmet needs. *Neuro-oncology* 2008;10(1):61-72.
37
- 38
39 377 7. Ståhl P, Fekete B, Henoch I, et al. Health-related quality of life and emotional well-being
40
41 378 in patients with glioblastoma and their relatives. *Journal of Neuro-oncology* 2020;149:347-56.
42
- 43
44 379 8. Renovanz M, Maurer D, Lahr H, et al. Supportive care needs in glioma patients and
45
46 380 their caregivers in clinical practice: results of a multicenter cross-sectional study. *Frontiers in*
47
48 381 *neurology* 2018;9:763.
49
- 50
51 382 9. Liu GQ, Han JY, Song WJ, Wang Y. Research progress of yoga in symptom management
52
53 383 of cancer patients. *TMR Non-Drug Ther.* 2022;5(2):10. Doi: 10.53388/TMRND20220531010
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

384 10. Lin K-Y, Hu Y-T, Chang K-J, et al. Effects of yoga on psychological health, quality of life,
385 and physical health of patients with cancer: a meta-analysis. Evidence-Based Complementary
386 and Alternative Medicine 2011;1-12.

387 11. Gonzalez M, Pascoe MC, Yang G, et al. Yoga for depression and anxiety symptoms in
388 people with cancer: a systematic review and meta-analysis. Psycho-Oncology
389 2021;30(8):1196-208.

390 12. Milbury K, Li J, Weathers S-P, et al. Pilot randomized, controlled trial of a dyadic yoga
391 program for glioma patients undergoing radiotherapy and their family caregivers. Neuro-
392 Oncology Practice 2019;6(4):311-20.

393 13. Huberty J, Eckert R, Dueck A, et al. Online yoga in myeloproliferative neoplasm
394 patients: results of a randomized pilot trial to inform future research. BMC complementary
395 and alternative medicine 2019;19(1):1-12.

396 14. Addington EL, Sohl SJ, Tooze JA, et al. Convenient and Live Movement (CALM) for
397 women undergoing breast cancer treatment: Challenges and recommendations for internet-
398 based yoga research. Complementary therapies in medicine 2018;37:77-9.

399 15. Jentschke E, Rabe A, Hagemann C, et al. The YINOTA-trial: Efficacy of Yoga-intervention
400 in high grade glioma patients and their caregivers - patient-reported outcomes and serum
401 stress parameters In: Karger, editor. 35. Deutscher Krebskongress, Krebsmedizin:
402 Schnittstellen zwischen Innovation und Versorgung 13.-16.11.2022 Berlin Oncology Research
403 and Treatment 2022: 485

404 16. Cahn BR, Goodman MS, Peterson CT, et al. Yoga, meditation and mind-body health:
405 increased BDNF, cortisol awakening response, and altered inflammatory marker expression
406 after a 3-month yoga and meditation retreat. Frontiers in human neuroscience 2017;11:1-13.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

- 1
2
3 407 17. Kumar D. Role of yoga and meditation on serum DHEAS level in first year medical
4
5
6 408 students. International Journal of Research in Medical Sciences 2018;6(6):2018-22.
7
8 409 18. Thirthalli J, Naveen G, Rao M, et al. Cortisol and antidepressant effects of yoga. Indian
9
10 410 journal of psychiatry 2013;55(3):405-8.
11
12
13 411 19. Kabat-Zinn J. Gesund durch Meditation. Das große Buch der Selbstheilung mit MBSR.
14
15 412 Knaur Menssana; 2013.
16
17
18 413 20. Zetzel T, Renner A, Pittig A, et al. Yoga effectively reduces fatigue and symptoms of
19
20 414 depression in patients with different types of cancer. Supportive Care in Cancer 2021;29:2973-
21
22 415 82.
23
24
25 416 21. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized
26
27 417 anxiety disorder: the GAD-7. Archives of internal medicine 2006;166(10):1092-7.
28
29
30 418 22. Hinz A, Klein AM, Brähler E, et al. Psychometric evaluation of the Generalized Anxiety
31
32 419 Disorder Screener GAD-7, based on a large German general population sample. Journal of
33
34 420 affective disorders 2017;210:338-44.
35
36
37 421 23. Mehnert A, Herschbach P, Berg P, et al. Progredienzangst bei Brustkrebspatientinnen-
38
39 422 Validierung der Kurzform des Progredienzangstfragebogens PA-F-KF. Zeitschrift für
40
41 423 Psychosomatische Medizin und Psychotherapie 2006;52(3):274-88.
42
43
44 424 24. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity
45
46 425 measure. Journal of general internal medicine 2001;16(9):606-13.
47
48
49 426 25. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research
50
51 427 and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical
52
53 428 trials in oncology. JNCI: Journal of the National Cancer Institute 1993;85(5):365-76.
54
55
56 429 26. Nolte S, Waldmann A, Liegl G, et al. Updated EORTC QLQ-C30 general population norm
57
58 430 data for Germany. European Journal of Cancer 2020;137:161-70.
59
60

1
2
3 431 27. Taphoorn MJ, Claassens L, Aaronson NK, et al. An international validation study of the
4
5 432 EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and
6
7
8 433 symptoms in brain cancer patients. European Journal of Cancer 2010;46(6):1033-40.
9
10 434 28. Preanalytics and shipping of hair samples for steroid analysis [online]. [https://tu-](https://tu-dresden.de/mn/psychologie/ifap/biopsychologie/ressourcen/dateien/labor/instructions-on-labelling-and-shipping-hair-samples?lang=de)
11
12 [dresden.de/mn/psychologie/ifap/biopsychologie/ressourcen/dateien/labor/instructions-on-](https://tu-dresden.de/mn/psychologie/ifap/biopsychologie/ressourcen/dateien/labor/instructions-on-labelling-and-shipping-hair-samples?lang=de)
13
14 [labelling-and-shipping-hair-samples?lang=de](https://tu-dresden.de/mn/psychologie/ifap/biopsychologie/ressourcen/dateien/labor/instructions-on-labelling-and-shipping-hair-samples?lang=de) (accessed: 27.02.2023).
15
16 436
17
18 437 29. Hardoerfer K, Jentschke E. Effect of Yoga Therapy on Symptoms of Anxiety in Cancer
19
20 438 Patients. Oncol Res Treat 2018;41(9):526-32.
21
22
23 439 **Trial status**
24
25
26 440 This trial is at protocol version 4, dated 05.07.2021.
27
28
29 441 **Trial registration data set**
30
31
32 442 See Supplementary file 1.
33
34
35 443 **Ethics approval and consent to participate**
36
37
38 444 The study conforms to the principles outlined in the Declaration of Helsinki. The study protocol
39
40 445 was approved by the Ethics Committee of the University Würzburg on 26.10.2021 (No.185/18-
41
42 446 me). In addition, the study is registered in the German Register of Clinical Trials (No.
43
44 447 DRKS00029554, 08/2022). Any changes to the study protocol must be approved by the
45
46 448 responsible ethics committee and reported to the German Clinical Trials Registry. Potential
47
48 449 participants will be informed about the study verbally and in writing. Written informed
49
50 450 consent must be given for study participation (see Supplementary file 2).
51
52
53
54
55
56 451 **Consent for publication**
57
58
59 452 Not applicable.
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

453 **Availability of data and materials**

454 Only members of the research team will have access to the final data set. There are no data
455 sharing plans.

456 **Competing interests**

457 The authors declare that they have no competing interests.

458 **Funding**

459 No external funding/institutional budget. This publication was supported by the Open Access
460 Publication Fund of the University of Würzburg. This funding source played no part in
461 designing the study and will not be involved in its execution, analyses, interpretation of the
462 data, or the decision to submit results.

463 **Authors' contributions**

464 EJ is the psychological study director and AK is the medical study director. CH and JS will
465 supervise the collection of the biomarkers and analyze them. AR is responsible for the
466 implementation and the coordination of the study. All authors read and approved the final
467 manuscript.

468 **Acknowledgements**

469 The authors would like to thank Dr. med. Miriam Ratliff, Neurooncology Center Mannheim,
470 Neurosurgical Clinic, University Hospital Mannheim;

471 Prof. Dr. med. Giles Hamilton Vince, Neurosurgical Clinic, Aschaffenburg-Alzenau Hospital, Dr.
472 med. Donato Daniel Martellotta, Neurosurgical Clinic, Aschaffenburg-Alzenau Hospital;

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

473 Prof. Dr. med. Martin Glas, Department of Clinical Neurooncology, Department of Neurology,
474 University Hospital Essen, PD Dr. med. Sied Kebir, Department of Clinical Neurooncology,
475 Department of Neurology, University Hospital Essen, Dr. Sarina Agkatsev, DPhil, Department
476 of Clinical Neurooncology, Department of Neurology, University Hospital Essen;

477 Prof. Dr. med. Ehab Shiban, Department of Neurosurgery, University Hospital Augsburg, PD
478 Dr. med. habil. Björn Sommer, Department of Neurooncology, Clinic for Neurosurgery,
479 University Hospital Augsburg, Dr. med. Ina Konietzko, Clinic for Neurosurgery, University
480 Hospital Augsburg;

481 Prof. Dr. med. Georg Karpel-Massler, Clinic for Neurosurgery, University Hospital Ulm and Dr.
482 biol. hum. Stephanie Otto, Comprehensive Cancer Center Ulm, University Hospital Ulm for
483 their commitment to the multicentric collaboration.

484

485

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES) .

Table 2. Trial registration data

Data category	Information
Primary registry and trial identifying number	DRKS-ID: DRKS00029554
Date of registration in primary registry	22 August 2022
Source(s) of monetary or material support	University Hospital Würzburg, Comprehensive Cancer Center Mainfranken; institutional budgeted/no external funding
Primary sponsor	University Hospital Würzburg, Comprehensive Cancer Center Mainfranken
Contact for public queries	Dr. Elisabeth Jentschke (Jentschke_E@ukw.de)
Contact for scientific queries	Dr. Elisabeth Jentschke (Jentschke_E@ukw.de)
Public and scientific title	Efficacy of an online yoga-intervention in patients with a brain-derived tumor of WHO grades 3 & 4 and their caregivers
Countries of recruitment	Germany
Health condition(s) or problem(s) studied	Brain-derived tumors (WHO grades 3 & 4)
Intervention(s)	Study group: online yoga intervention Waiting control group: online yoga intervention after eight weeks of waiting
Key inclusion and exclusion criteria	Inclusion criteria: Patients with a brain-derived tumor (WHO grades 3 & 4, initial diagnosis and/or recurrent disease, 6 weeks after surgery at the earliest) and their caregivers, male and female, age of 18-years or older, regular access to a computer with internet access Exclusion criteria: Lack of German language abilities, severe cognitive, affective and physical limitations
Study type	Interventional Allocation: randomized Primary purpose: supportive care
Date of first enrolment	Enrollment is scheduled for the first quarter of 2024
Target sample size	140
Recruitment status	Recruiting planned
Primary outcome(s)	Anxiety (GAD-7) after intervention
Key secondary outcomes	Progression anxiety (PA-F-KF), quality of life (EORTC QLQ C30 + BN20), depression (PHQ-9), BDNF, DHEA/DHEAS, ferritin and hair cortisol after intervention and 3 months after the end of the intervention

Einwilligungserklärung zur Teilnahme an der YINOTA-O-Studie

(Yoga-Intervention bei Neuroonkologischen Tumorpatienten und deren Angehörigen - Online)

„Erforschung der Wirksamkeit einer Online-Yogatherapie bei Patient:innen mit hirneigenem Tumor WHO Grade 3 und 4 und deren Angehörigen“

für Patient:innen

Name:.....

Vorname:.....

Geburtsdatum:.....

E-Mail-Adresse:.....

Ich bin von Herrn / Frauüber den Inhalt der Studie „Erforschung der Wirksamkeit einer Online-Yogatherapie bei Patient:innen mit hirneigenem Tumor WHO Grade 3 und 4 und deren Angehörigen“ informiert worden.

Alle meine Fragen sind zu meiner Zufriedenheit beantwortet worden. Ich hatte ausreichend Zeit, um meine Entscheidung zur Studienteilnahme zu überdenken und frei zu treffen. Die Studie wird von Dr. Elisabeth Jentschke von der Universitätsklinik Würzburg geleitet.

Eine schriftliche Teilnehmerinformation wurde mir ausgehändigt. Darin wurde mir versichert, dass

- die Teilnahme freiwillig ist,
- ich die Teilnahme jederzeit ohne Angabe von Gründen und ohne Nachteile abbrechen kann,
- keine personenbezogenen Angaben (Name, Geburtsdatum, Adresse) an Dritte weitergegeben werden,
- meine Angaben anonym ausgewertet werden,
- die geltenden Datenschutzbestimmungen eingehalten werden und eine unbefugte Weitergabe oder Veröffentlichung meiner persönlichen Daten nicht zulässig ist,
- die erhobenen Daten an der Uniklinik Würzburg zusammengeführt und verarbeitet werden - in einer Form, in der Rückschlüsse auf meine Person nicht mehr möglich sind.

Ich bin bereit, während des Studienzeitraums je nach Gruppenzuteilung insgesamt 3- bzw. 4-mal (1x vor der Zuordnung, 1x vor dem Kurs, 1x zum Ende des Kurses sowie 3 Monate nach Ende des Kurses) je 20 ml Blut- sowie eine Haarprobe abzugeben, die im Labor auf molekulare Stressmarker untersucht werden.

☐ nein

☐ ja, beides

☐ nur Haarproben

☐ nur Blutproben

Ort, Datum

Unterschrift der/s Teilnehmerin/s

Teilnehmer:in

Ich bin damit einverstanden, dass medizinische Daten, wie in der Patienteninformation angegeben aus der Klinikakte entnommen werden. Ich möchte die Studie unterstützen und willige daher in die Teilnahme ein.

Ort, Datum

Unterschrift der/s Teilnehmerin/s

Aufklärende Person

Der/die Teilnehmer:in wurde von mir im Rahmen eines Gesprächs über das Ziel und den Ablauf der Studie sowie über die Risiken aufgeklärt. Ein Exemplar der Informationsschrift und der Einwilligungserklärung wird an den/die Teilnehmer:in ausgehändigt.

Ort, Datum

Unterschrift der aufklärenden Person



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
	2b	All items from the World Health Organization Trial Registration Data Set	Supplementary file 1
Protocol version	3	Date and version identifier	20
Funding	4	Sources and types of financial, material, and other support	21
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1, 21
	5b	Name and contact information for the trial sponsor	21
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	21
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	9, 13

Introduction

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	3-6
	6b	Explanation for choice of comparators	7
Objectives	7	Specific objectives or hypotheses	5-6
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	7, 9, 5

Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	6
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	6
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	7
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	8
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	8, 14
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	7
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	7, 10-12, 14
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	7

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	9
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	7
5				
6	Methods: Assignment of interventions (for controlled trials)			
7				
8	Allocation:			
9				
10	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	9
11				
12				
13				
14				
15				
16	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	9
17				
18				
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	9
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	9,13
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	See 17a
28				
29				
30				
31	Methods: Data collection, management, and analysis			
32				
33	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	10-13
34				
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	7
40				
41				
42				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	12-13
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	13
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	13
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	14
11				
12				
13				
14	Methods: Monitoring			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation why a DMC is not needed	n/a. The research team itself takes on the regular monitoring of the data, reducing the need for a separate committee (see page 7)
17				
18				
19				
20				
21				
22				
23				
24				
25				
26				
27				
28				
29		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	9
30				
31				
32	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	14
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the processes will be independent from investigators and the sponsor	n/a. The members of the study team monitor and discuss all processes. No external auditing is mandatory for this trial
2				
3				
4				
5				
6				
7				
8				
9				
10				
11				
12	Ethics and dissemination			
13				
14	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	14
15				
16				
17	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial monitoring, regulatory bodies, journals, etc.)	14
18				
19				
20				
21	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	15
22				
23				
24				
25		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	n/a. No ancillary studies.
26				
27				
28	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	12-13
29				
30				
31	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	21
32				
33				
34	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	13-14
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				

Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a (The risks of harm to participants in this study are minor and no compensation for harm is necessary)
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, health care professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	15
	31b	Authorship eligibility guidelines and any intended use of professional writers	15
	31c	Plans, if any, for granting public access to the full protocol, participant-level data sets, and statistical code	2
Appendices			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Supplementary file 2 (German)
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	13-14

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons “Attribution-NonCommercial-NoDerivs 3.0 Unported” license.

BMJ Open

Study protocol for a multicenter randomized controlled trial evaluating the efficacy of an online yoga-intervention in high-grade glioma patients and their caregivers: The YINOTA-O-trial

Journal:	BMJ Open
Manuscript ID	bmjopen-2023-075698.R2
Article Type:	Protocol
Date Submitted by the Author:	25-Mar-2024
Complete List of Authors:	Rabe, Antonia; University Hospital Wurzburg, Psychooncology Keßler, Almuth Friederike; University Hospital Wurzburg, Neurosurgical Clinic and Polyclinic, Department of Neurosurgery Hagemann, Carsten; University Hospital Wurzburg, Neurosurgical Clinic and Polyclinic, Department of Neurosurgery, Section Experimental Neurosurgery Schubert, Jörg; University Hospital Wurzburg, Internal Medicine Center, Central Laboratory Jentschke, Elisabeth ; University Hospital Wurzburg, Psychooncology
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Mental health
Keywords:	Quality of Life, Depression & mood disorders < PSYCHIATRY, Anxiety disorders < PSYCHIATRY, Head & neck tumours < ONCOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Study protocol for a multicenter randomized controlled trial evaluating the efficacy of an**
2 **online yoga-intervention in high-grade glioma patients and their caregivers: The YINOTA-O-**
3 **trial**

4 Antonia Rabe¹, Almuth Friederike Keßler², Carsten Hagemann³, Jörg Schubert⁴, Elisabeth
5 Jentschke¹

6 ¹ University Hospital Würzburg, Comprehensive Cancer Center Mainfranken, Department of
7 Psychooncology, Josef-Schneider-Straße 6, 97080 Würzburg, Germany

8 ²University Hospital Würzburg, Neurosurgical Clinic and Polyclinic, Department of
9 Neurosurgery, Josef-Schneider-Straße 11, 97080 Würzburg, Germany

10 ³University Hospital Würzburg, Neurosurgical Clinic and Polyclinic, Department of
11 Neurosurgery, Section Experimental Neurosurgery, Josef-Schneider-Straße 11, 97080
12 Würzburg, Germany

13 ⁴University Hospital Würzburg, Internal Medicine Center, Central Laboratory, Oberdürrbacher
14 Straße 6, 97080 Würzburg, Germany

15 Correspondence to Dr. phil. Elisabeth Jentschke: jentschke_e@ukw.de

16 **Introduction:** High-grade glioma patients and their caregivers often suffer from distress and a
17 lower quality of life. Results from studies with patients with mixed cancer entities suggest that
18 yoga can be an effective support. However, it is unclear whether this also applies to high-grade
19 glioma patients and their caregivers. This study aims to investigate the effects of mindfulness-
20 based online yoga for patients and their caregivers on emotional distress, quality of life and
21 stress-associated physiological parameters compared to a waiting control group (WCG).

Methods & analysis: The study is designed as a multicenter randomized controlled trial. Adult glioma patients (CNS WHO grades 3 & 4) and their caregivers will be recruited. Examined yoga instructors deliver the intervention (1 h/week) in a synchronous format over 8 weeks via video conferencing. The WCG will receive standard care during the 8-week waiting period. Data will be collected before and after the end of the intervention and another 3 months later using questionnaires as well as blood serum and hair samples to evaluate biochemical stress parameters. Primary outcome is self-reported generalized anxiety and secondary outcomes are self-reported progression anxiety, depression, quality of life as well as BDNF, DHEA/DHEAS, Ferritin and hair cortisol. We hypothesize better outcomes in the intervention group (IG) compared to the WCG at all measurement points. 70 patients and 70 caregivers will be recruited consecutively. Primary endpoints are significant effect detections in the Generalized Anxiety Disorder Scale-7 of patients and caregivers at the end of the intervention. Analyses of covariance will be performed to analyze treatment effects.

Ethics and dissemination: The Ethics Committee of the University of Würzburg approved the YINOTA-O study on 26.10.2021 (No.185/18-me). Results will be presented at conferences and published in peer-reviewed journals.

Trial registration: German Clinical Trials Register (No. DRKS00029554, 08/2022).

Strengths and limitations of this study

- Simultaneous collection of subjective questionnaire data and objective physiological parameters
- Implementation of a tailored yoga intervention designed specifically to meet the unique needs of cancer patients

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

44 • The inclusion in the study without pre-screening for the identification of distressed
45 patients and caregivers may influence the detection of treatment effects

46 • The inclusion criteria regarding the type of disease (glioma patients CNS WHO grades
47 3 & 4) and the phase of the disease (diagnosis or recurrence) may induce higher
48 variance of the experienced symptoms among the participants

49 **Introduction**

50 The most recent version of the WHO Classification of Tumors of the Central Nervous System
51 [1] reflects the rapid advances in the understanding of brain tumors [2]. While a better
52 understanding of the pathophysiology of these tumors may have a positive impact on the
53 treatment [3], the treatment options for high-grade gliomas remain limited.

54 At the time of diagnosis, glioma patients often report cognitive deficits, seizures, headaches,
55 dizziness, and motor deficits [4]. As the disease progresses, drowsiness, dysphagia, confusion,
56 and aphasia expand the list of symptoms [4] and can reduce the patients’ autonomy [5].
57 Family members frequently take on the role of caregivers, conducting “physically,
58 emotionally, socially and/or financially demanding” tasks [6]. Thus the diagnosis of a high
59 grade glioma imposes a burden and significant reduction in quality of life for both the patients
60 and their caregivers. Ståhl and colleagues examined the extent of anxious and depressive
61 symptoms as well as health-related quality of life in both glioblastoma patients and their
62 caregivers before surgery [7]. Caregivers reported significantly inferior health-related quality
63 of life, more anxiety, and more depressive symptoms than the patients did. These findings are
64 consistent with those of previous studies [e.g. 8]. They imply that high-grade glioma patients
65 as well as their caregivers should be offered support to deal with disease-related psychological
66 distress.

Yoga is increasingly recognized as a complementary therapy for improving quality of life and cancer-related symptoms [9]. In recent years, several meta-analyses evaluated the effectiveness of yoga on anxiety and depression in cancer patients [10, 11]. Lin et al. as well as Gonzalez et al. reported significant medium effects of yoga on anxiety and significant medium to large effects on depression compared to the control conditions [10,11]. Most studies were conducted with breast cancer patients which is why no meta insights can be derived for the glioma patient population.

One referenced study examined a yoga intervention for glioma patients in an on-site setting [12]. Milbury et al. studied the feasibility of a dyadic yoga program for high-grade glioma patients and their caregivers during radiotherapy as well as its effects on cancer-related symptoms [12]. Comparing the intervention group and the waiting control group, patients in the intervention group showed significantly lower levels of depression and a significantly higher mental quality of life at post-assessment. In the caregivers' intervention group treatment effects were even more pronounced with a large effect size for improvement in depression. These results are encouraging but due to the on-site course format, require the physical presence of participants at the course location. Seizures can limit the patients' mobility and thereby impede their participation in supportive services on site. Alternatively, services, which can be attended from home, e.g. in an online format, could facilitate access supportive care for the target group. To date, only few studies were published examining online yoga interventions [13, 14]. None of them concern the group of glioma patients. The initial indications of feasibility cannot be generalized to brain tumor patients as they have brain tumor-specific symptoms like motor deficits [4] that need to be dealt with. In order to provide individual support from the yoga teachers, a synchronous online format seems appropriate for the target group but has not yet been investigated. It allows interaction with

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

91 the instructor as well as simultaneous supervision. To evaluate the feasibility of such an
92 intervention for both patients and their caregivers, a monocentric pilot study was conducted
93 in 2020, demonstrating its practicality and participant satisfaction [15].

94 The use of subjective measurement tools for assessing potential effects of yoga interventions
95 on anxiety and depression seems appropriate, given the subjective nature of these criteria.
96 Nonetheless, it remains unclear whether intervention effects are also detectable at the
97 biological level. Initial indications of the effects of yoga interventions on biological parameters
98 are derived from studies involving non-clinical populations [16, 17, 18] as well as patients with
99 myeloproliferative neoplasms [13]; evidence for glioma patients and their caregivers is
100 missing.

101 The purpose of this study is to explore the potential benefits of mindfulness-based yoga for
102 high-grade glioma patients and their caregivers. It aims to determine if participating in an 8-
103 week online intervention program can significantly reduce emotional distress and improve the
104 quality of life and stress-associated physiological parameters. In this regard, the following
105 research questions will be examined:

106 1. Primary research question

107 Does an eight-week online yoga intervention for high-grade glioma patients and their
108 caregivers reduce self-reported generalized anxiety symptoms directly after the
109 intervention compared to a WCG, and do these improvements persist three months
110 after the intervention? *We hypothesize that compared to participants in the WCG,*
111 *participants in the IG will report significantly fewer generalized anxiety symptoms both*
112 *immediately post-intervention and at the three-month follow-up.*

2. Secondary research question

Does such an intervention reduce self-reported fear of progression, depressive symptoms, quality of life and stress-associated physiological parameters (BDNF, DHEA/DHEAS, ferritin, hair cortisol) directly after the intervention compared to a WCG, and do these improvements persist three months after the intervention? We *hypothesize that the outcomes of participants in the intervention group will be superior to those of participants in the WCG in all aspects both immediately post-intervention and at the three months follow-up.*

Methods

Participants

Eligible for the study are adult (≥ 18 years) patients with glioma CNS WHO grades 3 & 4 (initial diagnosis or recurrence) treated in participating hospitals in Germany (University Hospital Würzburg, University Hospital Mannheim, Aschaffenburg-Alzenau Hospital, University Hospital Augsburg) and their caregivers. Patients are eligible to participate at any time point of treatment, but we recommend joining the yoga program not earlier than six weeks after surgery. Prerequisite for participation is regular access to a mobile device with internet access. Exclusion criteria are insufficient German language skills and serious cognitive, affective, or physical impairments. The study physicians and staff consider exclusion criteria during the recruitment process. Participants are advised not to concurrently engage in other supportive interventions for psychological distress throughout the duration of the study.

Study centers

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

134 Study centers are only eligible to participate in this study if they have the ability to process

135 blood serum samples and store them in a deep-freezer at -80 degrees. Moreover, a positive

136 ethics approval from the hospital's internal ethics committee and the execution of a

137 cooperation agreement are mandatory. Other clinics in Germany, excluding those mentioned,

138 are still in the process of fulfilling these requirements.

139 Study design and measurement points in time

140 This is a multicentric randomized controlled trial with an IG and a WCG. First, the IG receives

141 the 8-week online yoga intervention delivered by videoconference (Zoom Video

142 Communications). Subsequently, the WCG receives the same intervention. During the waiting

143 period, the WCG receives the medical standard of care and if needed additional psychological

144 and supportive care. Psychological support is provided by the psycho-oncology service as the

145 standard procedure, either following a positive result from a routine distress screening (for

146 inpatients) or at the request of the patient or their relatives. Other support services (e.g.

147 nutritional counselling) will also be provided at request. Brochures in the hospital provide

148 information about the services and contact details. Measurement points for the IG are: Before

149 randomization (T1), at the end of the intervention (T2) and 3 months after the last scheduled

150 yoga class (T4). Measurement points for the WCG are: Before randomization (T1), at the end

151 of the intervention of the IG / before the start of the intervention of the WCG (T2), at the end

152 of the intervention (T3) and 3 months after the last scheduled yoga class (T5). At each

153 measurement point in time, questionnaire data as well as a blood serum and hair samples will

154 be collected (Table 1). Study staff will supervise the status of data collection. Participant data

155 will be collected within a two-week timeframe before start and after end of the intervention.

156 In case of missing data, participants will be reminded by telephone up to three times. This also

157 applies to the follow-up. The planned start of the study is April 2024 and the expected end of
 158 the study is April 2026. This trial is at protocol version 4, dated 05.07.2021. Table 1 shows the
 159 study workflow.

Table 1. Schedule of enrolment, interventions, and assessments, according to Spirit 2013 guidelines

	Enrolment	Before allocation	After T1	Post-allocation			
TIMEPOINT	$-T_1$	T1		T2	T3 (only WCG)	T4 (only IG)	T5 (only WCG)
ENROLMENT:							
Eligibility screen	x						
Informed consent	x						
Allocation			x				
INTERVENTIONS:							
Online Yoga (IG)				↔			
Online Yoga (WCG)					↔		
ASSESSMENTS:							
socio-demographic data		x					
Medical data		x		x	x	x	x
Generalized anxiety		x		x	x	x	x
Fear of progression (only patients)		x		x	x	x	x
Depression		x		x	x	x	x
Quality of Life Questionnaire +		x		x	x	x	x

<i>Brain Module (only patients)</i>							
<i>BDNF, DHEA/DHEAS, ferritin, hair cortisol</i>		x		x	x	x	x
<i>Evaluation</i>						x	x

Patient and public involvement statement

The study was inspired by the positive experiences of a relative of a brain tumor patient with yoga during the disease and developed in exchange with her. Feedback from participants after the pilot study [15] was considered in the multicenter study.

Yoga intervention

It is recommended that participation in the study is discussed with a physician in advance to determine if yoga is appropriate for the participant's medical condition and to address any specific concerns related to the participant's medical condition. Yoga classes are held once a week for 60 minutes. Patients and caregivers will be taught successively in separate groups of 10 participants per group to ensure that caregivers are potentially nearby in case patients require support. As recommended in the literature [14], the groups will be closed groups. The intervention is based on the mindfulness-based hatha yoga described by Jon Kabatt-Zinn [19]. The intervention is carried out by certified yoga instructors (>200 units). The classes consist of a sequence of breathing exercises (pranayama), physical exercises (asanas) and meditation, which is repeated in each lesson. The exercises were selected in such a way that even patients with advanced disease can perform them with a mindful practice. The intervention is described in detail in Zetzl et al. [20]. For the sake of standardization of the yoga classes, yoga instructors are trained in advance by video-support, demonstrating all the exercises provided.

Alternative variations of the exercises will be discussed during the training session for participants who may face challenges in performing certain exercises due to impairments. In addition, a booklet is available, describing all exercises and providing important information on possible cancer-specific and cancer non-specific contraindications. To minimize technical difficulties, participants will be offered a technical rehearsal, and they will receive instructions on using the video platform.

Sample-size calculation

Based on previous research [10], a Standardized Mean Difference (SMD) of 0.76 is expected for generalized anxiety in favor of the IG when comparing the IG to the control group. Consequently, a case number of $n=29$ per group ($\alpha=0.05$ and $\beta=0.20$) will be determined for a two-tailed independent samples t-test. Based on the dropout rates reported in the reference studies [12-13, 20], 70 patients and 70 relatives will be recruited.

Recruitment

Based on the defined inclusion criteria, physicians and research staff of participating study centers will search for potential participants via the centers' electronic medical record systems. Eligible persons will be informed personally about the study during their outpatient consultation by their doctor or a member of the study team. The patients' caregivers – if not present at the outpatient visit - will be informed by telephone. If patients and/or their caregivers are interested in study participation, they will receive the written participation information and the consent form. They approve their participation by signing the latter and sending it by mail to the study coordinator. Recruitment will be concluded once the required sample size is reached.

Randomization and allocation concealment

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Participants will be consecutively enrolled in the study and randomly assigned to the IG or WCG. Utilizing a computer-generated list of random numbers ensures a close balance of the group sizes at any time during the trial by external blocked randomization (allocation rate 1:1). The list is generated and managed by an employee of the University Hospital Würzburg who is not involved in the study. If both patients and their caregivers participate in the intervention, they are randomized as a pair. For every block of 20 patients and 20 caregivers, 20 participants (10 patients, 10 caregivers) will be allocated to each arm of the trial. The study coordinator will request the results of the randomization after the initial survey is completed and convey it to the participants. Participants are then no longer blinded. If there is a likelihood of missing two sessions, randomization will be delayed.

Data collection, management, and analysis

Data collection

An online questionnaire, blood serum samples and hair samples are used to collect the required data. The online questionnaire is created and administered using the EvaSys evaluation software. Participants can access it via a web-link. On the first page of the online questionnaire, participants are instructed to enter their assignment code, which they received in advance per e-mail.

Primary outcomes

Self-reported generalized anxiety: The German version of the Generalized Anxiety Scale (GAD-7) [21] is used to assess anxious symptoms. Participants are asked to indicate the frequency of perceived impairment by seven symptoms on a 4-point Likert scale (0="not at all" to 4="almost every day") in the last two weeks. The internal consistency is

224 Cronbachs $\alpha = 0.85$, indicating high reliability [22]. A sum value is calculated from all items
225 (range: 0-21). The higher the value, the greater the severity of the anxiety.

226 Secondary outcomes

227 *Self-reported fear of progression:* The patient questionnaire contains a short form of the Fear
228 of Progression Questionnaire (FoP-Q-SF) with 12 items (PA-F-KF). The answers are given on a
229 five-point Likert scale (1="never"; 5="very often"). Good reliability (Cronbachs $\alpha = 0.87$) and
230 validity were demonstrated in a German sample of breast cancer patients [23]. For analysis, a
231 sum value is calculated from all items (range: 12-60). The higher the value, the greater the
232 severity of the anxiety.

233 *Self-reported depression:* The Patient Health Questionnaire-9 (PHQ-9) consists of nine items
234 regarding the impairment due to depressive symptoms in the past two weeks. A 4-point Likert
235 scale is used (0="not at all" to 3="almost every day"). Good reliability (Cronbachs $\alpha = 0.89$)
236 and validity were demonstrated in a sample of patients with different medical conditions [24].
237 For analysis, a sum score is calculated from all items. The higher the value, the greater the
238 severity of depression (range: 0-27).

239 *Self-reported Quality of Life:* The European Organization for Research and Treatment of Cancer
240 (EORTC) Quality of Life questionnaire C30 (QLQ-C30) plus brain module (BN20) are used to
241 assess quality of life. The EORTC QLQ-C30 consists of 30 questions that can be assigned to ten
242 subscales. Two items assessing overall health and overall quality of life in the last week, both
243 of which were scored from 1="very poor" to 7="excellent". The appropriateness of the other
244 items is assessed on a 4-point Likert scale (1="not all" to 4="very much"). The validity and
245 reliability of the questionnaire could be demonstrated [25]. Although this is a cancer-specific
246 questionnaire, norm values are also available for a healthy German sample [26].

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The brain module is recommended for use in conjunction with the EORTC QLQ-C30 [27]. It consists of additional 20 items that can be assigned to seven single-item scales and four multi-item scales. A standardized point value is calculated by linear transformation. Scores range from 0-100. A higher score for the function scales indicates better functionality, and a higher score for the symptom scales indicates greater symptom burden. Adequate psychometric properties were demonstrated [27].

Stress parameters: To assess stress-associated physiological parameters, the study physicians or the study nurses collect blood serum samples from the participants (20 ml EDTA blood) and pencil-thick strands of hair (2cm, refers to the area of the scalp, length at least 1cm) from the back of the head [28]. The sample procurement points in time for blood serum and hair samples (hair length up to 7 cm) correspond to the time of the questionnaire assessments. For long hair (7 cm or more), one single pencil thick strand of hair will be collected at the last blood serum collection appointment. Hair sampling will not be performed in case of TTFields- or cortisone-treatment.

Sociodemographic and health data: As possible covariates and for sample description, participants will be asked at T1 to provide information regarding marital status, education and occupation, previous experiences with yoga and expectations regarding the classes as well as mental illnesses. In addition, at each measurement point in time, questions are asked about medication, actual treatment, and the course of the disease. Patients' routine medical data (type and stage of disease, time of diagnosis, treatment) will be collected from the electronic patient file of the respective clinic by responsible study staff. For the continuous development of the intervention, participants will be asked about their general and specific satisfaction with individual features of the intervention at the end of the intervention (selected exercises,

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

duration of a single yoga class, and instruction of the exercises, group size, and atmosphere in the class).

Data management

All questionnaire data as well as all blood serum and hair samples are marked with a pseudonym instead of the participant's name and a password-protected digital allocation list is used. The allocation list includes the participant's first and last name, date of birth, the clinic where the participant was recruited, the e-mail address under which the participant would like to be contacted, and whether the participant is a patient or a caregiver. This data is taken from the consent form. The study coordinator, who is responsible for the assignment list, creates a pseudonymization code for each participant according to a predefined procedure. This is required to retrieve the data needed for sample description from the hospital information system as well as to process the blood serum and hair samples. During the period of the assignment, the research data will be considered "personal data" and data protection laws will be complied with.

At the end of data collection, the questionnaire data will be exported from the online platform used for the survey by the study coordinator and saved password-protected on a computer at the University Hospital of Würzburg. After that, the questionnaire data is deleted from the online platform. The site coordinators transmit the selected routine medical data of the participating patients to the study coordinator in accordance with data protection regulations. After data analysis, the assignment lists as well as the consent declarations are deleted. Deletion of the site-specific assignment lists provided will be confirmed in writing by the site coordinators. The raw data of the study will be destroyed after 10 years in accordance with data protection regulations. To prevent loss of study data, the study coordinator performs a

regular backup. Hair samples are enclosed in aluminum foil after collection and the part close to the root is fixed with a paper clip. Samples are stored dry and dark at room temperature in a cardboard box/large envelope. The blood and serum samples, if not completely consumed for molecular stress marker determination, will be stored frozen at -80°C for the duration of the study. After completion of data collection, the samples will be picked up from the participating centers by the medical study management of the University Hospital Würzburg and brought to the laboratory of the Section Experimental Neurosurgery of the Department of Neurosurgery, University Hospital Würzburg. The analysis of the biological data is blinded. All sample remnants will be destroyed after completion of the study.

Analysis

Intent-to-treat as well as per-protocol analyses should be performed. Participants who attended at least six out of the eight sessions are considered completers. The data of the patients and the relatives are analyzed separately. To test for group differences covariance analyses with adjustment for baseline values of outcome variables will be performed. To calculate the adherence rate, the average number of sessions the participants attended will be calculated. We use η^2 as the effect size calculated in covariance analyses. $\eta^2=0.0099$ was assessed as a small effect, $\eta^2=0.0588$ as a medium effect, and $\eta^2=0.1379$ as a large effect according to Cohen. To analyze changes between post-intervention and follow-up two-tailed t-tests are performed. Standardized mean differences are used to calculate the effect size. A p-value of <0.05 is considered significant. Missing values due to drop-out will be analyzed by pair-wise deletion.

Data analysis is performed using International Business Machines Corporation (IBM) Statistical Package for Social Sciences (SPSS) Statistics for Windows version 22.

Monitoring

The yoga instructors will document adverse effects, such as injuries, in writing immediately after each class, including necessary adjustments to the exercises. The documentation of presence is used to calculate the adherence rate.

Ethics and dissemination

The Ethics Committee of the University of Würzburg approved the described study protocol on 26.10.2021 (No.185/18-me). Important changes in the protocol will be passed on to the responsible ethics committee as well as the German Register of Clinical Trials and will be described in study reports. The investigation conforms to the principles outlined in the Declaration of Helsinki. Potential study participants will be informed about all relevant aspects of the study (goals, processes, data protection). This information will be provided verbally and in writing by the research staff. In particular, the voluntary nature of the study participation as well as the possibility of discontinuing the study at any time without giving reasons and without any disadvantages for the treatment are emphasized. In the consent form, interested participants are specifically asked for their consent to provide blood serum and hair samples. They can consent either to provide both samples, to donate blood serum samples or hair samples only, or refuse to give such samples. Even without providing samples, participation in the study is possible. The consent form also asks for an e-mail address for further contact. Participation in the study is only possible with written consent. After completion of the study, a joint publication of the study results has been contractually agreed between the participating clinics. There are no publication restrictions. No professional writers are planned.

Discussion

1
2
3 338 The disease and its treatment often stress high-grade glioma patients and their caregivers.
4
5
6 339 Depressive and anxious symptoms and reduced quality of life are frequently reported in the
7
8 340 literature [7, 8]. Sometimes the emotional health of the caregivers is worse than that of the
9
10 341 patients [8]. This multicenter study will offer high-grade glioma patients and their caregivers
11
12
13 342 a mindfulness-based yoga course by examined yoga instructors, which has already proven
14
15 343 helpful in previous studies with patients with mixed cancer entities [20, 29]. However, due to
16
17 344 the heterogeneous sample characteristics of these previous studies, it remains unclear
18
19
20 345 whether this yoga intervention is also helpful for improving emotional well-being and quality
21
22
23 346 of life of high-grade glioma patients. In addition, the effectiveness of a mindfulness-based
24
25 347 yoga intervention has not yet been studied for caregivers. Generally, yoga studies that
26
27 348 exclusively include patients with high-grade glioma and their caregivers are rare [12].
28
29
30 349 Therefore, in this study the intervention will be provided exclusively for glioma patients CNS
31
32 350 WHO grades 3 and 4 and their caregivers.
33
34
35 351 The aim of this randomized controlled study is to investigate whether significant changes of
36
37 352 self-reported anxious and depressive symptoms and in quality of life are detectable after the
38
39
40 353 intervention in the IG compared to the WCG. As in previous yoga studies [e.g. 11], self-report
41
42
43 354 questionnaires will be used for this purpose. Furthermore, stress-associated physiological
44
45 355 parameters extracted from blood and hair samples are also evaluated in this study. A possible
46
47 356 demonstration of the effects of mindfulness-based online yoga therapy on a biochemical level
48
49
50 357 could highlight the value of yoga in the supportive therapy of cancer patients and should be
51
52
53 358 further investigated in future studies. Although the inclusion criteria regarding the type of
54
55 359 disease (glioma patients CNS WHO grades 3 & 4) and the phase of the disease (diagnosis or
56
57 360 recurrence) facilitate timely recruitment of the participants, they may also induce higher
58
59
60 361 variance of the experienced limitations among the participants. In favor of greater

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

homogeneity, specification of inclusion criteria regarding characteristics of the tumors based on the updated WHO Classification [1] is considered for this and recommended for future studies.

Due to the Covid-19 pandemic the yoga intervention, which we planned originally as an in-person course was adapted to an online format. Today, we expect this to actually bring other advantages for the vulnerable target group in comparison to on-site yoga. The participation in the online course may increase the sense of autonomy of patients with reduced mobility, as they do not need to be driven to class by family members. It also conserves caregivers' limited time resources due to caregiving and may reduce stress from travel. For this reason, the online yoga therapy if proven effective could be an attractive treatment approach for high-grade glioma patients and their caregivers even beyond the Covid-19 pandemic.

References

1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. *Neuro-oncology* 2021;23(8):1231-51.
2. Horbinski C, Berger T, Packer RJ, et al. Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours. *Nature Reviews Neurology* 2022;18(9):515-29.
3. Wen PY, Packer RJ. The 2021 WHO classification of tumors of the central nervous system: clinical implications. *Neuro-oncology* 2021;23(8):1215-7.
4. IJzerman-Korevaar M, Snijders TJ, de Graeff A, et al. Prevalence of symptoms in glioma patients throughout the disease trajectory: a systematic review. *Journal of neuro-oncology* 2018;140:485-96.
5. Sterckx W, Coolbrandt A, de Casterlé BD, et al. The impact of a high-grade glioma on everyday life: a systematic review from the patient's and caregiver's perspective. *European Journal of Oncology Nursing* 2013;17(1):107-17.
6. Schubart JR, Kinzie MB, Farace E. Caring for the brain tumor patient: family caregiver burden and unmet needs. *Neuro-oncology* 2008;10(1):61-72.

1
2
3 389 7. Ståhl P, Fekete B, Henoch I, et al. Health-related quality of life and emotional well-being
4 390 in patients with glioblastoma and their relatives. *Journal of Neuro-oncology* 2020;149:347-56.
5
6
7 391 8. Renovanz M, Maurer D, Lahr H, et al. Supportive care needs in glioma patients and
8 392 their caregivers in clinical practice: results of a multicenter cross-sectional study. *Frontiers in*
9 393 *neurology* 2018;9:763.
10
11
12 394 9. Liu GQ, Han JY, Song WJ, Wang Y. Research progress of yoga in symptom management
13 395 of cancer patients. *TMR Non-Drug Ther.* 2022;5(2):10. Doi: 10.53388/TMRND20220531010
14
15
16 396 10. Lin K-Y, Hu Y-T, Chang K-J, et al. Effects of yoga on psychological health, quality of life,
17 397 and physical health of patients with cancer: a meta-analysis. *Evidence-Based Complementary*
18 398 *and Alternative Medicine* 2011:1-12.
19
20
21 399 11. Gonzalez M, Pascoe MC, Yang G, et al. Yoga for depression and anxiety symptoms in
22 400 people with cancer: a systematic review and meta-analysis. *Psycho-Oncology*
23 401 2021;30(8):1196-208.
24
25
26 402 12. Milbury K, Li J, Weathers S-P, et al. Pilot randomized, controlled trial of a dyadic yoga
27 403 program for glioma patients undergoing radiotherapy and their family caregivers. *Neuro-*
28 404 *Oncology Practice* 2019;6(4):311-20.
29
30
31 405 13. Huberty J, Eckert R, Dueck A, et al. Online yoga in myeloproliferative neoplasm
32 406 patients: results of a randomized pilot trial to inform future research. *BMC complementary*
33 407 *and alternative medicine* 2019;19(1):1-12.
34
35
36 408 14. Addington EL, Sohl SJ, Tooze JA, et al. Convenient and Live Movement (CALM) for
37 409 women undergoing breast cancer treatment: Challenges and recommendations for internet-
38 410 based yoga research. *Complementary therapies in medicine* 2018;37:77-9.
39
40
41 411 15. Jentschke E, Rabe A, Hagemann C, et al. The YINOTA-trial: Efficacy of Yoga-intervention
42 412 in high grade glioma patients and their caregivers - patient-reported outcomes and serum
43 413 stress parameters In: Karger, editor. 35. Deutscher Krebskongress, Krebsmedizin:
44 414 Schnittstellen zwischen Innovation und Versorgung 13.-16.11.2022 Berlin Oncology Research
45 415 and Treatment 2022: 485
46
47
48 416 16. Cahn BR, Goodman MS, Peterson CT, et al. Yoga, meditation and mind-body health:
49 417 increased BDNF, cortisol awakening response, and altered inflammatory marker expression
50 418 after a 3-month yoga and meditation retreat. *Frontiers in human neuroscience* 2017;11:1-13.
51
52
53 419 17. Kumar D. Role of yoga and meditation on serum DHEAS level in first year medical
54 420 students. *International Journal of Research in Medical Sciences* 2018;6(6):2018-22.
55
56
57
58
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

18. Thirthalli J, Naveen G, Rao M, et al. Cortisol and antidepressant effects of yoga. *Indian journal of psychiatry* 2013;55(3):405-8.
19. Kabat-Zinn J. *Gesund durch Meditation. Das große Buch der Selbstheilung mit MBSR.* Knaur Menssana; 2013.
20. Zetzel T, Renner A, Pittig A, et al. Yoga effectively reduces fatigue and symptoms of depression in patients with different types of cancer. *Supportive Care in Cancer* 2021;29:2973-82.
21. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Archives of internal medicine* 2006;166(10):1092-7.
22. Hinz A, Klein AM, Brähler E, et al. Psychometric evaluation of the Generalized Anxiety Disorder Screener GAD-7, based on a large German general population sample. *Journal of affective disorders* 2017;210:338-44.
23. Mehnert A, Herschbach P, Berg P, et al. Progredienzanxiety bei Brustkrebspatientinnen- Validierung der Kurzform des Progredienzanxietyfragebogens PA-F-KF. *Zeitschrift für Psychosomatische Medizin und Psychotherapie* 2006;52(3):274-88.
24. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *Journal of general internal medicine* 2001;16(9):606-13.
25. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *JNCI: Journal of the National Cancer Institute* 1993;85(5):365-76.
26. Nolte S, Waldmann A, Liegl G, et al. Updated EORTC QLQ-C30 general population norm data for Germany. *European Journal of Cancer* 2020;137:161-70.
27. Taphoorn MJ, Claassens L, Aaronson NK, et al. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. *European Journal of Cancer* 2010;46(6):1033-40.
28. Preanalytics and shipping of hair samples for steroid analysis [online]. <https://tu-dresden.de/mn/psychologie/ifap/biopsychologie/ressourcen/dateien/labor/instructions-on-labelling-and-shipping-hair-samples?lang=de> (accessed: 27.02.2023).
29. Hardoerfer K, Jentschke E. Effect of Yoga Therapy on Symptoms of Anxiety in Cancer Patients. *Oncol Res Treat* 2018;41(9):526-32.

1
2
3 453 **Trial registration data set**
4

5
6 454 See Supplementary file 1.
7
8

9
10 455 **Ethics approval and consent to participate**
11
12

13 456 The study conforms to the principles outlined in the Declaration of Helsinki. The study protocol
14
15 457 was approved by the Ethics Committee of the University Würzburg on 26.10.2021 (No.185/18-
16
17 458 me). In addition, the study is registered in the German Register of Clinical Trials (No.
18
19 459 DRKS00029554, 08/2022). Any changes to the study protocol must be approved by the
20
21
22 460 responsible ethics committee and reported to the German Clinical Trials Registry. Potential
23
24 461 participants will be informed about the study verbally and in writing. Written informed
25
26 462 consent must be given for study participation (see Supplementary file 2).
27
28
29

30
31 463 **Consent for publication**
32
33

34 464 Not applicable.
35
36

37 465 **Availability of data and materials**
38
39

40 466 Only members of the research team will have access to the final data set. There are no data
41
42 467 sharing plans.
43
44

45 468 **Competing interests**
46
47

48
49 469 The authors declare that they have no competing interests.
50
51

52 470 **Funding**
53
54

55 471 This publication was supported by the Open Access Publication Fund of the University of
56
57 472 Würzburg (grant number: N/A).
58
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES)

Authors' contributions

EJ is the psychological study director and AK is the medical study director. CH and JS will supervise the collection of the biomarkers and analyze them. AR is responsible for the implementation and the coordination of the study. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to thank Dr. med. Miriam Ratliff, Neurooncology Center Mannheim, Neurosurgical Clinic, University Hospital Mannheim;

Prof. Dr. med. Giles Hamilton Vince, Neurosurgical Clinic, Aschaffenburg-Alzenau Hospital, Dr. med. Donato Daniel Martellotta, Neurosurgical Clinic, Aschaffenburg-Alzenau Hospital;

Prof. Dr. med. Martin Glas, Department of Clinical Neurooncology, Department of Neurology, University Hospital Essen, PD Dr. med. Sied Kebir, Department of Clinical Neurooncology, Department of Neurology, University Hospital Essen, Dr. Sarina Agkatsev, DPhil, Department of Clinical Neurooncology, Department of Neurology, University Hospital Essen;

Prof. Dr. med. Ehab Shiban, Department of Neurosurgery, University Hospital Augsburg, PD Dr. med. habil. Björn Sommer, Department of Neurooncology, Clinic for Neurosurgery, University Hospital Augsburg, Dr. med. Ina Konietzko, Clinic for Neurosurgery, University Hospital Augsburg;

Prof. Dr. med. Georg Karpel-Massler, Clinic for Neurosurgery, University Hospital Ulm and Dr. biol. hum. Stephanie Otto, Comprehensive Cancer Center Ulm, University Hospital Ulm for their commitment to the multicentric collaboration.

Table 1. Trial registration data

Data category	Information
Primary registry and trial identifying number	DRKS-ID: DRKS00029554
Date of registration in primary registry	22 August 2022
Source(s) of monetary or material support	University Hospital Würzburg, Comprehensive Cancer Center Mainfranken; institutional budged/no external funding
Primary sponsor	University Hospital Würzburg, Comprehensive Cancer Center Mainfranken
Contact for public queries	Dr. Elisabeth Jentschke (Jentschke_E@ukw.de)
Contact for scientific queries	Dr. Elisabeth Jentschke (Jentschke_E@ukw.de)
Public and scientific title	Efficacy of an online yoga-intervention in patients with a brain-derived tumor of WHO grades 3 & 4 and their caregivers
Countries of recruitment	Germany
Health condition(s) or problem(s) studied	Brain-derived tumors (WHO grades 3 & 4)
Intervention(s)	Study group: online yoga intervention Waiting control group: online yoga intervention after eight weeks of waiting
Key inclusion and exclusion criteria	Inclusion criteria: Patients with a brain-derived tumor (WHO grades 3 &4, initial diagnosis and/or recurrent disease, 6 weeks after surgery at the earliest) and their caregivers, male and female, age of 18-years or older, regular access to a computer with internet access Exclusion criteria: Lack of German language abilities, severe cognitive, affective and physical limitations
Study type	Interventional Allocation: randomized Primary purpose: supportive care
Date of first enrolment	Enrollment is scheduled for the first quarter of 2024
Target sample size	140
Recruitment status	Recruiting planned
Primary outcome(s)	Anxiety (GAD-7) after intervention
Key secondary outcomes	Progression anxiety (PA-F-KF), quality of life (EORTC QLQ C30 + BN20), depression (PHQ-9), BDNF, DHEA/DHEAS, ferritin and hair cortisol after intervention and 3 months after the end of the intervention

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

Einwilligungserklärung zur Teilnahme an der YINOTA-O-Studie

(Yoga-Intervention bei Neuroonkologischen Tumorpatienten und deren Angehörigen - Online)

„Erforschung der Wirksamkeit einer Online-Yogatherapie bei Patient:innen mit hirneigenem Tumor WHO Grade 3 und 4 und deren Angehörigen“

für Patient:innen

Name:

Vorname:

Geburtsdatum:

E-Mail-Adresse:

Ich bin von Herrn / Frau über den Inhalt der Studie „Erforschung der Wirksamkeit einer Online-Yogatherapie bei Patient:innen mit hirneigenem Tumor WHO Grade 3 und 4 und deren Angehörigen“ informiert worden.

Alle meine Fragen sind zu meiner Zufriedenheit beantwortet worden. Ich hatte ausreichend Zeit, um meine Entscheidung zur Studienteilnahme zu überdenken und frei zu treffen. Die Studie wird von Dr. Elisabeth Jentschke von der Universitätsklinik Würzburg geleitet.

Eine schriftliche Teilnehmerinformation wurde mir ausgehändigt. Darin wurde mir versichert, dass

- die Teilnahme freiwillig ist,
- ich die Teilnahme jederzeit ohne Angabe von Gründen und ohne Nachteile abbrechen kann,
- keine personenbezogenen Angaben (Name, Geburtsdatum, Adresse) an Dritte weitergegeben werden,
- meine Angaben anonym ausgewertet werden,
- die geltenden Datenschutzbestimmungen eingehalten werden und eine unbefugte Weitergabe oder Veröffentlichung meiner persönlichen Daten nicht zulässig ist,
- die erhobenen Daten an der Uniklinik Würzburg zusammengeführt und verarbeitet werden - in einer Form, in der Rückschlüsse auf meine Person nicht mehr möglich sind.

Ich bin bereit, während des Studienzeitraums je nach Gruppenzuteilung insgesamt 3- bzw. 4-mal (1x vor der Zuordnung, 1x vor dem Kurs, 1x zum Ende des Kurses sowie 3 Monate nach Ende des Kurses) je 20 ml Blut- sowie eine Haarprobe abzugeben, die im Labor auf molekulare Stressmarker untersucht werden.

☐ nein

☐ ja, beides

☐ nur Haarproben

☐ nur Blutproben

Ort, Datum

Unterschrift der/s Teilnehmerin/s

Teilnehmer:in

Ich bin damit einverstanden, dass medizinische Daten, wie in der Patienteninformation angegeben aus der Klinikakte entnommen werden. Ich möchte die Studie unterstützen und willige daher in die Teilnahme ein.

Ort, Datum

Unterschrift der/s Teilnehmerin/s

Aufklärende Person

Der/die Teilnehmer:in wurde von mir im Rahmen eines Gesprächs über das Ziel und den Ablauf der Studie sowie über die Risiken aufgeklärt. Ein Exemplar der Informationsschrift und der Einwilligungserklärung wird an den/die Teilnehmer:in ausgehändigt.

Ort, Datum

Unterschrift der aufklärenden Person



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
	2b	All items from the World Health Organization Trial Registration Data Set	Supplementary file 1
Protocol version	3	Date and version identifier	8
Funding	4	Sources and types of financial, material, and other support	21
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	1, 22
	5b	Name and contact information for the trial sponsor	21
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	N/A [see 5a-5b]
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	11, 14-15

1	Introduction			
2				
3	Background and	6a	Description of research question and justification for undertaking the trial, including summary of relevant	3-6
4	rationale		studies (published and unpublished) examining benefits and harms for each intervention	
5				
6		6b	Explanation for choice of comparators	7
7				
8	Objectives	7	Specific objectives or hypotheses	5-6
9				
10	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),	5-7, 10
11			allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	
12				
13	Methods: Participants, interventions, and outcomes			
14				
15				
16	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will	6
17			be collected. Reference to where list of study sites can be obtained	
18				
19	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and	6-7
20			individuals who will perform the interventions (eg, surgeons, psychotherapists)	
21				
22	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be	7-10
23			administered	
24				
25		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose	10
26			change in response to harms, participant request, or improving/worsening disease)	
27				
28		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence	16
29			(eg, drug tablet return, laboratory tests)	
30				
31		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	6
32				
33	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood	11-15
34			pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg,	
35			median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen	
36			efficacy and harm outcomes is strongly recommended	
37				
38	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for	8
39			participants. A schematic diagram is highly recommended (see Figure)	
40				
41				
42				
43				
44				
45				
46				

1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	10
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	10
5				
6	Methods: Assignment of interventions (for controlled trials)			
7				
8	Allocation:			
9				
10	Sequence	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	10
11	generation			
12				
13				
14				
15				
16	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	11
17	concealment			
18	mechanism			
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	11
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	11
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N/A [see 17a]
28				
29				
30				
31	Methods: Data collection, management, and analysis			
32				
33	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	11-14
34	methods			
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	7
40				
41				
42				
43				
44				
45				
46				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	14-15
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	15
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	N/A [No additional analyses are planned]
9				
10				
11				
12				
13		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	15
14				
15				
16				
17	Methods: Monitoring			
18				
19	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	N/A [The research team itself takes on the regular monitoring of the data, reducing the need for a separate committee]
20				
21				
22				
23				
24				
25				
26				
27				
28				
29				
30		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A [Recruitment will be concluded once the required sample size is reached]
31				
32				
33				
34				
35				
36				
37	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	16
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the processes will be independent from investigators and the sponsor	N/A [The members of the study team monitor and discuss all processes. No external auditing is mandatory for this trial]
2				
3				
4				
5				
6				
7				
8				
9				
10				
11				
12	Ethics and dissemination			
13				
14	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	1
15				
16				
17	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial runners, sponsors, journals, regulators)	16
18				
19				
20				
21	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	10
22				
23				
24				
25		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A [No ancillary studies]
26				
27				
28	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	14
29				
30				
31	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	21
32				
33				
34	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	21
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Ancillary and post-	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial	N/A [The risks of
2	trial care		participation	harm to
3				participants in this
4				study are minor
5				and no
6				compensation for
7				harm is necessary]
8				
9				
10	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, health care professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	2
11				
12				
13				
14		31b	Authorship eligibility guidelines and any intended use of professional writers	16
15				
16		31c	Plans, if any, for granting public access to the full protocol, participant-level data sets, and statistical code	2, 21
17				
18				
19	Appendices			
20				
21	Informed consent	32	Model consent form and other related documentation given to participants and authorised surrogates	Supplementary file
22	materials			2 (German)
23				
24	Biological	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular	13-15
25	specimens		analysis in the current trial and for future use in ancillary studies, if applicable	
26				

27 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.

28 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons

29 “[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)” license.

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46